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INTRODUCTION 
1.0 BIOANALYTICAL AND BIOEQIVALANCE STUDIES 
The design, performance, and evaluation of bioavailability and 
bioequivalence studies have received major attention from academia, the 
pharmaceutical industry and health authorities over the last couple of decades. 
Comparison of therapeutic performance of two medicinal products containing the 
same active substance is critical for assessing the possibility of supplanting an 
innovator with any essentially similar medicinal product. In practice, demonstration 
of bioequivalence is generally the most appropriate method of substantiating 
therapeutic equivalence between medicinal products. (Rechard F. Venn 2004). 
This thesis deals with the “Bioanalytical Method Development and 
Validation for the Estimation of Ezetimibe in Human Plasma by LC-MS/MS”. 
Before discussing the experimental results, a brief introduction to Biopharmaceutical 
analysis, analysis of drugs and metabolites in biological media, Preliminary 
treatment of biological samples, Extraction procedures for drugs and metabolites 
from biologic samples, estimation of drugs in biological sample by LC-MS, 
quantitative techniques in LC-MS, Bioavailability(BA) and Bioequivalence 
studies(BE), Methods to document BA and BE, Comparison of BA measures in BE 
studies, Moieties to be measured in BA and BE studies,  and literature survey will be 
briefly reviewed here. Biopharmaceutical analysis deals with determining trace 
(microgram or less) levels of organic and selected inorganic medicaments in 
biologic fluids.  
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The drugs are absorbed orally and peak plasma concentration is reached at a 
certain time. The drug is subsequently distributed, metabolized, and excreted and the 
drug concentration declines over a period of time depending on the elimination half-
life. The bioequivalence studies conducted to investigate the pharmacokinetic 
parameters of two pharmaceutical formulation of the same drug and to demonstrate 
the equivalence of their pharmacokinetic parameters. 
Bioavailability Studies (BA) focus on determining the process by which a 
drug is released from the oral dosage form and moves to the site of action. BA data 
provide an estimate of the fraction of the drug absorbed, as well as its subsequent 
distribution and elimination. BA can be generally documented by a systemic 
exposure profile obtained by measuring drug and/or metabolite concentration in the 
systemic circulation over time.  
Bioequivalence studies (BE) involves comparison between a test (T) and 
reference (R) drug product, where T and R can vary, depending on the comparison 
to be performed (e.g. to be marketed dosage form versus clinical trial material, 
generic drug versus reference listed drug, drug product changed after approval 
versus drug product before the change). For two orally administered drug products 
to be bioequivalent, the active drug ingredient or active moiety in the test product 
should exhibit the same rate and extent of absorption as the reference drug product. 
BE information is required to ensure therapeutic equivalence between a 
pharmaceutically equivalent test drug product and a reference listed drug.  
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1.1 NEED FOR BIO-EQUIVALENCE STUDIES  
1.1.1 Applications for products containing new active substances 
During the development of a new active substance (new chemical entity) intended 
for systemic action, bioequivalence studies are necessary as bridging studies 
between, 
(i) Pivotal and early clinical trial formulations;  
(ii) Pivotal clinical trial formulations,  
Especially those used in the dose finding studies, and the to-be-marketed 
medicinal product. (Dieter Hauschke and Volker, 2006) 
1.1.2 Applications for products containing approved active substances 
In-vivo bioequivalence studies are needed when there is a risk that possible 
differences in bioavailability may result in therapeutic in-equivalence. The 
Committee for Proprietary Medicinal Products (CPMP) guidance (2001) devotes an 
entire section to the necessity of bioequivalence studies for various dosage forms, 
taking into consideration the concepts underlying the Biopharmaceutics 
Classification System, i.e., high solubility, high permeability for the active 
substance, and high dissolution rate for the medicinal product. 
 This section also addresses special topics such as 
 Exemptions from bioequivalence studies in the case of oral immediate release   
forms (in vitro dissolution data as part of a bioequivalence waiver) Post approval 
changes. 
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 Dose proportionality of immediate release oral dosage forms (bioequivalence 
assessment for only one dose strength). 
 Suprabioavailability (which necessitates reformulation to a lower dosage 
strength, otherwise the suprabioavailable product may be considered as new 
medicinal product, the efficacy and safety of which have to be supported by 
clinical studies). 
1.1.3 Applications for modified release forms essentially similar to a marketed 
modified release forms 
The requirements for modified release forms are stated in the CPMP Note for 
Guidance on Modified Release Oral and Transdermal Dosage Forms (1999), which 
differentiates between prolonged, delayed and transdermal release forms. Prolonged 
release formulations can be assessed as bioequivalent on the basis of single-dose and 
multiple-dose studies, which are designed to demonstrate that 
 The test formulation exhibits the claimed prolonged release characteristics of the 
reference. 
 The active drug substance is not released unexpectedly from the test formulation 
(dose dumping). 
 Performance of the test and reference formulation is equivalent after single dose 
and at steady state. 
 The effect of food on the in vivo performance is comparable for both 
formulations when a single-dose study is conducted comparing equal doses of 
the test formulation with those of the reference formulation administered 
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immediately after a predefined high fat meal. This study should be conducted 
with the same strength(s) as those of the pivotal bioequivalence studies. 
In the case of prolonged release single unit formulations with multiple 
strengths, a single-dose study under fasting conditions is required for each strength. 
Studies at steady state may be conducted with the highest strength only, if certain 
criteria for extrapolating bioequivalence studies (linear pharmacokinetics, same 
qualitative composition, etc.) are fulfilled. 
For multiple unit formulations of a medicinal product showing linear 
pharmacokinetics with multiple strengths, a single-dose study under fasting 
conditions on the highest strength is sufficient, provided that the compositions of the 
lower strengths are proportional to that of the highest strength, the formulations 
contain identical beads or pellets, and the dissolution profiles are acceptable. 
For delayed release formulations, postprandial bioequivalence studies are 
necessary as food can influence the absorption of an active substance administered 
in an enteric-coated formulation. 
The bioequivalence of a transdermal drug delivery system (TDDS) in 
comparison to the innovator’s product should usually be assessed after single dose 
as well as after multiple dose administration. When marketing authorization of 
multiple strengths is required, the bioequivalence study can be performed with the 
highest dosage strength provided that exact proportionality in the formulation is 
given, i.e., the composition is the same, and the strength is proportional to the 
effective surface area of the patch, and that there is an acceptable in vitro release test 
(CPMP, 1999). 
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2.0 FACTORS TO BE CONSIDERED 
2.1 Storage Requirements for Biologic Samples 
In order to avoid decomposition or other potential chemical changes in the 
drugs to be analyzed, biologic samples should be frozen immediately upon 
collection and thawed before analysis.  When drugs are susceptible to plasma 
esterase, the addition of esterase inhibitors, such as sodium fluoride, to blood 
samples immediately after collection helps to prevent drug decomposition. 
When collecting and storing biologic samples, the analyst should be varying 
of artefacts from tubing or storage vessels that can contaminate the sample. For 
example, plastic-ware frequently contains the high boiling liquid Bis-(2-ethylhexyl) 
phthalate, similarly, the plunger-plugs of vacutainers are known to contain 
tri-butoxyethyl phosphate, which can interfere in certain drug analyses. 
In the case of faeces, lyophilization of the sample before storage is highly 
desirable unless prior investigations have revealed little or no reactivity of the drug 
components with the endogenous intestinal micro-organisms. 
2.2 Preliminary Treatment of Biologic Samples 
In most cases, preliminary treatment of a sample is needed before the analyst 
can proceed to the measurement step. Analyses are required for drug in samples as 
diverse as plasma, urine, faeces, saliva, bile, sweat, and seminal fluid. Each of these 
samples has its own set of factors that must be considered before an appropriate 
pretreatment method can be selected. Such factors as texture and chemical 
composition of the sample, degree of drug-protein binding, chemical stability of the 
drug, and types of interferences can affect the final measurement step. 
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2.2.1 Protein Precipitation or Denaturation 
Biologic materials such as plasma, feces, and saliva contain significant 
quantities of protein, which can bind a drug. The drug may have to be free from 
protein before further manipulation. Protein Denaturation is important, because the 
presence of proteins, lipids, salts, and other endogenous material in the sample can 
cause rapid deterioration of HPLC columns and also interfere the assay. Protein 
denaturation procedures include the use of tungstic acid, ammonium sulfate, heat, 
alcohol, trichloroacetic acid, and perchloric acid. 
Methanol and acetonitrile frequently have been used as protein denaturants 
of biologic samples. Methanol sometimes is preferred because it produces a 
flocculent precipitate and not the gummy mass obtained with acetonitrile. Methanol 
also gives a clearer supernate and may prevent the drug entrapment that can be 
observed after acetonitrile precipitation.  
Ultrafiltration and dialysis procedures also have been used to remove 
proteins from biologic fluids. These procedures are not widely used because they are 
slow. 
2.2.2 Hydrolysis of Conjugates 
The presence-of drug metabolites as conjugates, such as glucuronides and 
sulfates, in biologic samples cannot be ignored. The effect of a drug depends to a 
considerable extent on the biotransformation that occurs in the human body. 
Therefore, it may be important to isolate the actual conjugates. Samples containing 
either glucuronide acetals or sulfate esters are usually pretreated using enzymatic or 
acid hydrolysis. The unconjugated metabolites that result from the hydrolysis 
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procedure are less hydrophilic than their conjugates and usually can be extracted 
from the biologic matrix. 
A nonspecific acid hydrolysis can be accomplished by heating a biologic 
sample for 30 min at 90 to 100°C in 2 to 5N hydrochloric acid. Upon cooling, the 
pH of the sample can be adjusted to the desired level and the metabolite removed by 
solvent extraction. Particularly stable conjugates sometimes require hydrolysis in an 
autoclave. 
2.2.3 Homogenization  
For samples containing insoluble protein, such as muscle or other related 
tissues, a homogenization or solubilizing step using 1N hydrochloric acid may be 
required before treating the sample further. For gelatinous samples such as seminal 
fluid or sputum, liquefaction is achieved via sonication. A solid sample such as feces 
can be homogenized with a minimum amount of methanol. Homogenization is 
usually performed with a blade homogenizer (e.g., Waring Blender).  
3.0 EXTRACTION PROCEDURES FOR DRUGS AND METABOLITES 
FROM BIOLOGIC SAMPLES 
After pre treating biologic material, the next step is usually the extraction of 
the drugs from the biologic matrix. All separation procedures use one or more 
treatments of matrix-containing solute with some fluid. If the components are a 
liquid (extracting solvents) and a solid (e.g., lyophilized feces), it is an example of 
liquid-solid extraction. If the extraction involves two liquid phases, it is an example 
of liquid-liquid extraction. (Richard F.Venn 2004) 
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3.1 Liquid-Solid Extraction 
Liquid - solid extractions occur between a solid phase and a liquid phase, 
either phase may initially contain the drug substance. Among the solids that have 
been used successfully in the extraction (usually via adsorption) of drugs from liquid 
samples are XAD-2 resin, charcoal, alumina, silica gel, and aluminum silicate.  
Sometimes the drugs are contained in a solid phase, such as in lyophilized 
specimens. Liquid-solid extraction is often particularly suitable for polar compounds 
that would otherwise tend to remain in the aqueous phase. The method could also be 
useful for amphoteric compounds that cannot be extracted easily from water. 
Factors governing the adsorption and elution of drugs from the resin column 
include solvent polarity; flow rate of the solvent through the column, and the degree 
of contact the solvent has with the resin beads. In the adsorption process, the 
hydrophobic portion of the solute that has little affinity for the water phase is 
preferentially adsorbed on the resin surface while the hydrophilic portion of the 
solute remains in the aqueous phase. Alteration in the lipophilic / hydrophilic 
balance within the solute or solvent mix, and not within the resin, affects adsorption 
of the solute. Biologic samples can be prepared for cleanup by passing the sample 
through the resin bed where drug (metabolite) components are adsorbed and finally 
eluted with an appropriate solvent.  The liquid solid extraction method provides a 
convenient isolation procedure for blood samples, thus avoiding solvent extraction, 
protein precipitation, drug losses, and emulsion formulation. It is possible, however, 
that strong drug-protein binding could prevent sufficient adsorption of the drug to 
resin.  
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3.2 Dehydration Methods 
An aqueous biologic sample is treated with a sufficient quantity of 
anhydrous salt (sodium or magnesium sulfate) to create a "dried" mix. This mix is 
then extracted with a suitable organic solvent to remove the desired drug or 
metabolite. 
3.3 Liquid-Liquid Extraction 
Liquid-liquid extraction is probably the most widely used technique because 
 The analyst can remove a drug or metabolite from larger concentrations of 
endogenous materials that might interfere with the final analytic determination.   
 The technique is simple, rapid, and has a relatively small cost factor per sample.  
 The extract containing the drug can be evaporated to dryness, and the residue 
can be redissolved in a smaller volume of a more appropriate solvent. In this 
manner, the sample becomes more compatible with a particular analytic 
methodology in the measurement step, such as a mobile phase in HPLC 
determinations.  
 The extracted material can be redissolved in small volumes (e.g., 100 to 500 µl 
of solvent), thereby extending the sensitivity limits of an assay.   
 It is possible to extract more than one sample concurrently.  
 Near quantitative recoveries (90% or better) of most drugs can be obtained 
through multiple or continuous extractions. 
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Partitioning or distribution of a drug between two possible liquid phases can 
be expressed in terms of a partition or distribution coefficient, usually called P. A 
partition coefficient is constant only for a particular solute, temperature, and pair of 
solvents used. By knowing the P value for the extracted drug and the absolute 
volumes of the two phases to be utilized, the quantity of drug extracted after a single 
extraction can be obtained. In multiple extractions methodology, the original 
biologic sample is extracted several times with fresh volumes of organic solvent 
until as much drug as possible is obtained. Because the combined extracts now 
contain the total extracted drug, it is desirable to calculate the number of extractions 
necessary to achieve maximum extraction.  
3.3.1 Factors Affecting the Partition Coefficient 
Factors that influence partition coefficient and hence recovery of drugs in 
liquid-liquid extraction are choice of solvent, pH, and ionic strength of the aqueous 
phase. In almost all cases, one of the liquid phases is aqueous because of the nature 
of a biologic sample. The second liquid is selected by the analyst. It is highly 
desirable to select an organic solvent that shows great affinity for the drug analyzed, 
yet leaves contaminants or impurities in the aqueous or biologic phase. The solvent 
should be immiscible with an aqueous phase, should have less polarity than water, 
and should solubilize the desired extractable compound to a large extent. It should 
also have a relatively low boiling point so that it can be easily evaporated if 
necessary. Other considerations are cost, toxicity, flammability, and the nature of the 
solvent. If larger numbers of samples are to be extracted, the volume of solvent 
needed per sample can affect the overall cost of the assay procedure.  
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It is generally accepted that diethyl ether and chloroform are the solvents of 
choice for acidic and basic drugs, respectively, especially when the identity of the 
drugs in the samples is unknown. In these cases, any chemically neutral drugs are 
extracted into either solvent depending on their relative partition tendencies. Proper 
pH adjustment of a biologic sample permits quantitative conversion of an ionized 
drug to an un-ionized species, which is more soluble in a nonpolar solvent and 
therefore, extractable from an aqueous environment. In analyses that must determine 
a known drug or metabolite, the proper pH for extraction can be calculated from the 
Henderson-Hasselbalch equation using the pKa of the compound. If the species to 
be analyzed is unknown, the pH must be approximated based on the chemical nature 
of the suspected agent.  
Third Factor influencing extractability of drugs from biologic samples is 
ionic strength. Addition of highly water-soluble ionized salts, such as sodium 
chloride, to an aqueous phase creates a high degree of interaction between the water 
molecules and the inorganic ions in solution. Fewer water molecules are free to 
interact with a unionized drug.  
Therefore, the solubility of the drug in the aqueous phase decreases, thereby 
increasing the partitioning or distributing in favor of the non-polar or organic phase. 
The technique is commonly called “salting out”. Either mechanical or manual 
tumbling, rocking, or vigorous shaking of the samples can accomplish mixing of the 
aqueous-organic phases. The percent recovery of a drug vs. time and/or type of 
mixing should be investigated for each biologic sample. In many cases, vigorous 
shaking of a sample should be avoided because it leads to emulsification, which can 
be intractable to centrifugation. Emulsification is often observed when organic 
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solvents are used at basic pH whereas certain organic solvents such as n-hexane and 
diethyl ether are less emulsion-prone. 
Certain types of amphoteric drugs or drugs that possess extreme water 
solubility are not amenable to classic solvent extraction. In these cases, other types 
of analytic methodology such as ion-pairing must be adopted. The technique of 
back-extraction can be applied with success to the analysis of drugs in biologic 
samples. The purpose of the methodology is to further purify an extract by removing 
either drug or impurities by additional extractions.  
4.0 ANALYTICAL TECHNIQUES IN BIOANALYSIS 
Chromatography is a separation technique by which solutes of two or more 
components are separated by a dynamic differential migrational process. In a system 
consisting of two phases, one of which moves continuously in a given direction and 
in which individual components exhibit differential mobility due to difference in 
their adsorption or partition or molecular size etc. 
Methods for separation of Drugs and their metabolites in biological sample 
can be developed, provided one has knowledge about the nature of the Drug, its 
molecular weight, polarity, pKa, ionic character and the solubility parameter. An exact 
recipe for HPLC, however, cannot be provided because method development involves 
considerable trial and error procedures. The most difficult problem usually is where to 
start, what type of column to be used with what kind of mobile phase. Interfacing 
mass spectrometers with chromatographic separation techniques is one of the most 
sophisticated and sensitive technique used in detection and quantization of Drug and 
its active metabolite in biological fluid. (Dougles A Skoog, 1996) 
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4.1 Selection of Mobile Phase 
Since mobile phase governs solute –stationary phase interaction 
 Practical considerations dictate that it should not degrade the equipment or 
column packing .So strong acids; bases and halides should be avoided.  
 Chemical purity of sample is important factor. Since large volume of solvents 
are pumped through the column. Trace amount of impurities can easily 
concentrate in column and eventually detrimental to the result. So HPLC grade 
solvents only recommended to use in the analysis 
 Volatility should be considered if sample recovery is required and mass transfer 
between solvent and stationary phase will be reduced. 
Water, acetonitrile, ethanol, 2-propanol & methanol are widely used solvents. 
High concentration of THF (Tetrahydrofuran) as modifier should be used with extreme 
caution in APCI (Atmospheric Pressure Chemical Ionization) with heated nebulizer due 
to flammability air should not be used or auxiliary gas in APCI operation. 
4.2 Role of solvent type  
Chromatographic separations thus vary with solvent properties and are 
related to sample solubility, polarity and solvent strength. Solvents that interact 
strongly with the sample will increase the sample ion exit in the solvents and are not 
able to equilibrate with adsorbent surface. Changing the organic solvent will change 
the selectivity. In reverse phase, less polar solvent exhibit greater solvent strength 
than polar solvents. The solvents water (most polar), methanol, Acetonitrile and 
Tetrahydrofuran placed in ascending order of their polarity.  
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4.3 Selection of buffer and role of pH 
pH is another factor in resolution equation that will affect the selectivity of 
the  separation. In reverse phase HPLC, sample retention increases when the analyte 
is more hydrophobic .Thus when an acid (HA) or base (B) is ionized (converted in 
the form of unionized free or base) it becomes more hydrophilic and is less 
interactive with column binding sites.   
Thus when selecting a buffer for a given application the following 
considerations are important. The buffer capacity is dependent on the buffer pH, pKa 
and buffer concentration. Other properties such as volatility, solubility, stability of the 
buffer and its reactivity to the analytes play important role in chromatographic system.  
 Ammonium formate & ammonium acetate are suitable for buffer mobile phase 
in LC/MS/MS. Usually 2-10 mM concentration is adequate but concentration up 
to 50 mM can be used.  
 Ammonium acetate may be used to replace phosphate buffers, which are not 
recommended for LC/MS. 
 Ammonium adducts will frequently be observed in positive ion operation and 
formate or acetate ion adduct will be observed in negative ion operation.  
 All the ammonium buffers may enhance sensitivity of weakly acidic compound 
undergoing negative ion analysis. 
 Basic compounds will usually show an enhanced signal by lowering pH of 
mobile phase. Strong, volatile acid such as formic acid, acetic acid, 
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Triflouroacetic acid are recommended in concentration 0.1 to 1.0 % usually to 
enhance MS ionization but LC requirement may need higher concentration.   
 Addition of acid will suppress the negative ion signal intensity since weakly 
acidic compound will not be deprotonated in acidic solution.  
Triflouroacetic acid may be used in LC/MS especially for protein / peptide 
analysis but positive ion signals intensity is usually lower when formic acid is used. 
TFA and sulfonic acids should not be used for negative ion operation. Triethylamine 
may be used but it may suppress the ionization of less basic compound in positive 
ion operation (it gives an enhanced intense ion at m/z 102). It may be used in 
negative ion mode to enhance ionization of other compounds. 
4.4 Selection of column 
HPLC column is the important tool for separation of analytes .So the column 
must possess good selectivity, efficiency and reproducibility to provide good 
separation of analytes. Commonly used column are C-18, C-8, Phenyl, Cyano 
columns. They are chemically different bonded phase having different selectivity 
with same mobile phase. 
5.0 METHOD DEVELOPMENT  
Method development involves considerable trial and error procedures. 
 In general, one begins with reversed phase chromatography, when the 
compounds are hydrophilic in nature with many polar groups and are water-
soluble.  
Chapter 1 Introduction 
Dept. of Pharmaceutical Analysis 17 J.K.K. Nattraja College of Pharmacy 
 The pH of the mobile phase has to be selected in such a way that the compounds 
are not ionized. If the retention times are too short, then decrease 5 % of the 
organic phase concentration in the mobile phase, if the retention times are too 
long, an increase 5% of organic phase concentration in the mobile phase is 
needed.  
 Elution of Drug molecules can be altered by changing the polarity of the mobile 
phase. The elution strength of a mobile phase depends upon its polarity. Ionic 
samples (acidic or basic) can be separated only, if they are present in 
undissociated form. Dissociation of ionic samples may be suppressed by proper 
selection of pH.  
 Whenever acidic or basic samples are to be separated it is strongly advisable to 
control mobile phase pH by adding a buffer. PH of the buffer is to be adjusted 
before adding organic phase. The buffer selected for a particular separation 
should be used to control pH over the range of  pka ±1.0. 
 Optimizations can be started only after a reasonable chromatogram has been 
obtained. A reasonable chromatogram means that all the compounds are detected 
by more or less symmetrical peaks on the chromatogram.   
 During method development selection of column can be streamlined by starting 
with shorter columns (50 mm, 100 mm or even 150 mm).   By selecting a shorter 
column with an appropriate phase the run time can be minimized so that an 
elution order and an optimum mobile phase can be quickly determined.  The 
internal diameter of the column is also one factor is to be considered. 
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 Many laboratories use 4.6mm ID as standard one, but it is worth considering 
using 4mm ID column as an alternative. This 4 mm column requires only 75 % 
of the solvent consumption than that of 4.6 mm column.  
 Selecting an appropriate stationary phase can also help to improve the efficiency 
of method development.   For example, a C-8 phase (reversed phase) can 
provide a further time saving over a C-18 as it doesn’t retain the analytes as 
strongly as the C-18 phase. 
 For normal phase application cyano phases are most versatile. C-18 (250 x 4.6 
mm) column are more often used in laboratory. These columns are able to 
resolve a wide variety of compounds due to their selectivity and higher number 
of theoretical plates.  
 In bio-analysis the method development step additionally require the extraction 
trial in order to recover the analyte and internal standard from highly 
complicated biological matrix. One should have knowledge about the nature of 
the Drug, namely its molecular weight, polarity, pKa, ionic character and the 
solubility parameter.  
 Selection of internal standard should be on the basis of structural similarity, 
physicochemical properties related to the analyte to be quantified.  
Method optimization or Performance of selected method is checked by running three 
or more precision and accuracy batches and evaluating the results for meeting 
acceptance criteria for within run precision, accuracy and between run precision and 
accuracy.  
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Finally selected method has to be validated to see whether it does what it was 
intended to do; i.e. it must be validated through validation parameters. The validated 
bio-analytical method is then applied for quantitation of Drug and its metabolites at 
its LOQ level with suitable precision and accuracy in a reproducible manner.  
6.0 INSTRUMENTATION    
6.1 Liquid chromatography and mass spectrometry 
It is the way of interfacing the high vacuum domain of mass spectrometer with 
the condensed phase domain of liquid chromatography. (Marvin C. Mcmaster 2006) 
6.2 Need of LC system interfacing with mass spectrometer 
The separation is done prior to mass analysis because the mass spectrometer 
is incapable of directly determining every analyte in all type of sample.  The Liquid 
chromatography can be regarded as a part of preparative procedure required for 
sample clean up which improves linearity, accuracy and better sensitivity. Mass 
spectrometer provides greater selectivity and sensitivity for chromatographic 
development because endogenous matrix can co-elutes with analytes yet not 
interferes as long as these components possess precursor masses.  
The main purpose of interface is to evaporate the mobile phase and transfer 
the analytes from the higher pressure/atmospheric pressure at which 
chromatographic separation is achieved to the lower pressure required for the mass 
analysis. LC/MS is highly effective interface for coupling liquid chromatograph to 
the mass spectrometer. Mass spectrometer used as a detector system while liquid 
chromatograph taken as separation system.  
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BLOCK DIAGRAM OF LC – MS/MS 
 
6.2.1 Sample inlet system    
There are two opinions of a sample inlet system  
 The sample introduced as neutral species through a controlled vacuum leak 
followed by ionization in vacuum chamber. 
 Create the ion at atmospheric pressure and then introduced the ion in to the mass 
spectrometer through a controlled vacuum leak with aid of electrostatic this 
process is called API (atmospheric pressure ionization) provide best way when a 
dynamic coupling of liquid chromatograph done.  
API is largely responsible for dramatic growth of mass spectrometry in 
pharmaceuticals industry, so API-LC/MS system is now-a-days commonly used.  
6.2.2 Ionization source 
Ionization proceeds by two fundamental processes: 
 Loss/gain of an electron 
 Loss/gain of a charge particle  
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An odd electron ions is generated by the gain/loss of an electron. In vacuum 
generating method ionic species of identical nominal molecular weight differ only 
by the mass of an electron to the neutral specie from which it was generated. An 
even electron is produced by gain or loss of even electron specie from a molecule.  
There are four common modes of ionization  
 Electron ionization (EI) 
 Chemical ionization (CI) 
 Matrix-Assisted Laser desorption Ionization (MALDI) 
 Atmospheric pressure ionization (API)  
In LC/MS interfacing Atmospheric Pressure Ionization (API) is the potential 
Ionization techniques because 
 It gives softer ionization 
 It provide convenient interface with liquid chromatograph 
The less fragmentation of the molecular ions and a convenient interface with liquid 
chromatograph at ambient pressure to mass spectrometry at high vacuum. 
6.2.2.1 Type of API Source  
 Atmospheric Pressure Electro Spray Ionization 
 Atmospheric Pressure Chemical Ionization  
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6.2.2.1.1 Atmospheric Pressure Electro Spray Ionization  
It is an atmospheric ionization technique in which ions are generated in the 
solution phase by evaporation of carrier solvent and ions are produced in gas 
phase. An appropriate solvent from LC (liquid chromatographic) system is passed 
through a metal capillary to which a static DC voltage is applied to create ionization 
of effluents. When the solvent got evaporate the charge density increases creating 
columbic repulsion and subsequent dissociation of droplet. Further evaporation of 
droplet creates an environment in which charge transfer takes place from the solvent 
to the analytes. (Achille Cappiello 2006) Typically a voltage of 2.5 to 5 kV will be 
applied to generate an even electron ion in gas phase. This method is commonly 
used for high molecular compounds. Presently most of the designs rely on coaxial 
gas flow (nitrogen) which improves desolation. This source with coaxial gas flow 
are called nebulization assisted electro spray ionization. Low ionization is observed 
in this technique due to solvent clustering and analyte adduct formation, so this is 
most applicable for LC/MS system.  
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6.2.2.1.2 Atmospheric Pressure Chemical Ionization  
It is an ionization technique in which the ionization occurs not in vacuum but at 
atmospheric pressure. It is a gas phase ionization process where by gas phase 
molecules are isolated from the carrier solvent before ionization. Generally less 
polar compounds are ionized by this method. (Michaela Malm, 2000). 
       
 
Atmospheric Pressure Chemical Ionization 
6.2.3 Mass analyzer 
Any mass analyzer contains electrical or magnetic field or combination of 
two, which is capable of manipulating the trajectory of ions in a vacuum chamber. 
For any mass analyzer the analyte particle, should be charged in order to separate 
the ion from the other ions. There are so many type of analyzer used in MS system 
but specially Quadrupole analyzer is used frequently in the case of LC/MS/MS.     
6.2.3.1 Quadrupole Mass Analyzer 
It consists of two pair of electrically conducting rods/electrodes on to which 
a concurrent radio frequency (RF) and direct current (DC) voltage is applied. The 
rod consists of molybdenum or gold, diameter of 1 cm & 30 cm in length. Opposing 
quadrupole rods pairs are connected electrically such that they carry identical 
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RF/DC ratio. For a given RF/DC voltage ratio the quadrupole analyzer filter only the 
ion with in a selected mass/charge ratio have a stable trajectory as they pass from 
one quadrupole rod set to the other. If RF/DC is held constant only a narrow m/z 
range will transmit the quadrupole. In this configuration quadrupole mass analyzer 
act as a mass filter or quadrupole filter. In case of bioanalysis it is used as a tandem 
(MS/MS).  
It consists of a capillary interface for liquid introduction, a heated 
nebulization system and a high voltage corona needle, it require high liquid flow rate 
like 200 micro liter/min. 
Quadrupole Mass Analyzer 
 
 
 
 
Nebulisation of effluent is done by heated gas flow (nitrogen) generating gas 
phase molecules of both (effluent and analyte). A metal needle is placed between 
nebulization probe and first vacuum orifice.  A DC voltage is applied on needle 
which develops a charge from atmosphere and evaporated solvent, leads to 
production of ions in gas phase. The process of introducing the ions into the mass 
analyzer through differential pumping and their subsequent separation and detection 
are identical. This method used to improve ionization efficiency. This method is 
particularly useful for non-polar analyte or weakly polar analyte in normal phase.  
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Tandem means when two or more than two analyzer either of different type 
(TOF/Q) or the same type (Q/Q) configured. The quadrupole mass analyzer 
configured in tandem commonly called Triple Quadrupole Mass Analyzer. This 
configuration increases the inherent selectivity and capability of instrument 
exponentially. In between the two quadrupole a collision cell is used as a false 
quadrupole for the fragmentation of precursor ions. This cell is either hexapole or 
octapole not true quadrupole so this configuration is called as triple quadrupole.   
6.2.3.2 Ionization Polarity   
In API method either positive or negative charge ion can be generated. The 
type of ions generated is dependent on the charge of adduct gain or loss during 
ionization. e.g.: A positive DC voltage on the capillary will generate positive ion 
from the basic compound such as amine will favor the positively charged ions     
(protonated). A negative DC voltage produce negative ion from acidic compounds 
such as carboxylic acid will favor negatively charged ion (deprotonated).   
6.2.3.3 Tandem mass spectrometry 
Tandem mass spectrometry is also called as mass spectrometry-mass 
spectrometry because the instrument contain two mass analyzer in tandem. A 
collision cell is placed between the two analyzers. 
The basic approach of MS-MS is the measurement of mass to charge ratio of 
ions before and after the fragmentation of selected ions in collision cell with high-
pressure gas. This collision process is known as collision induced dissociation. The 
tandem arrangement allows the m/z relating to the analyte to be selected at first 
quadrupole and m/z characteristic of daughter ions to be selected at the second 
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quadrupole. This arrangement provides good selectivity and sensitivity. The first 
quadrupole is used to select the parent ion and fragmentation occurs in the collision 
cell. The fragmented ion goes to second quadrupole, which select the ions of the 
specific reaction product only.  
In this process the internal energy of analyte is increasing which induce the 
fragmentation this is achieved by collision activation. Collision with neutral gas 
molecules called collision induced dissociation (CID).  
 
 
 
 
 
 
 
 
6.2.3.4 CID is a two-step process: 
First collision when an ion translational energy is converted into internal 
energy to obtain an ion in excited state and a secondary slow unimolecular 
decomposition which yield various ion product from a number of competitive 
reaction. As a result there is increase in internal energy, leads to the fragmentation of 
ions. In case of CID the fragmentation of actually induced in a collision cell with 
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higher pressure. In principle two mass analyzers are required, one is for selecting the 
precursor ions from the ions generated in the ion source and other for analyzing the 
product ions after the collision for this approach is called tandem mass spectrometry. 
6.2.4 Detector  
The ions pass through the mass analyser and are then detected and 
transformed into causable signal by a detector. Detectors are able to generate from 
the incident ions an electric current that is proportional to their abundance. Detectors 
used in mass spectrometry were reviewed in 2005. The most common types of ion 
detectors are described below. (Edmond de Hoffmann 2004) 
 Photographic Plate 
 Faraday Cup 
 Electron Multipliers 
6.2.4.1 Photographic Plate 
The first mass spectrometers used photographic plates located behind the 
analyser as detectors. Ions sharing the same m/z ratio all reach the plate at the same 
place and the position of the spots allows the determination of their m/z values after 
calibration. The darkness of the spots gives an approximate value of their relative 
abundance. This detector, which allows simultaneous detection over a large m/z 
range, has been used for many years but is obsolete today. 
6.2.4.2 Faraday Cup 
A Faraday cup is made of a metal cup or cylinder with a small orifice. It is 
connected to the ground through a resistor. Ions reach the inside of the cylinder and 
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are neutralized by either accepting or donating electrons as they strike the walls. 
This leads to a current through the resistor. The discharge current is then amplified 
and detected. It provides a measure of ion abundance. 
Because the charge associated with an electron leaving the wall of the 
detector is identical to the arrival of a positive ion at this detector, secondary 
electrons that are emitted when an ion strikes the wall of the detector are an 
important source of errors if they are not suppressed. In consequence, the accuracy 
of this detector can be improved by preventing the escape of reflected ions and 
ejected secondary electrons. Various devices have been used to capture ions 
efficiently and to minimize secondary electron losses. For instance, the cup is coated 
with carbon because it produces few secondary ions. The shape of the cup and the 
use of a weak magnetic field prevent also any secondary electrons produced inside 
to exit. 
The disadvantages of this simple and robust detector are its low sensitivity 
and its slow response time. Indeed, the sensitivity of such detectors is limited by the 
noise of the amplifiers. Furthermore, this detector is not well adapted to ion currents 
that are not stable in the same time as during the scanning of the analyser because of 
its slow response time. These detectors are nevertheless very precise because the 
charge on the cylinder is independent of the mass, the speed and the energy of the 
detected ions. 
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6.2.4.3 Electron Multipliers 
At present, the most widely used ion detector in mass spectrometry is the 
electron multiplier (EM). In this detector, ions from the analyser are accelerated to a 
high velocity in order to enhance detection efficiency. This is achieved by holding 
an electrode called a conversion dynode at a high potential from ±3 to ±30 kV, 
opposite to the charge on the detected ions. A positive or negative ion striking the 
conversion dynode causes the emission of several secondary particles. These 
secondary particles can include positive ions, negative ions, electrons and neutrals.  
When positive ions strike the negative high-voltage conversion dynode, the 
secondary particles of interest are negative ions and electrons. When negative ions 
strike the positive high-voltage conversion dynode, the secondary particles of interest 
are positive ions. These secondary particles are converted to electrons at the first 
dynode. These are then amplified by a cascade effect in the electron multiplier to 
produce a current. The electron multipliers may be of either the discrete dynode or the 
continuous dynode type (channeltron, microchannel plate or microsphere plate) 
    
 
 
 
The discrete dynode electron multiplier is made up of a series of 12 to 20 
dynodes that have good secondary emission properties. These dynodes are held at 
decreasing negative potentials by a chain of resistors. The first dynode is held at a 
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high negative potential from−1 to−5 kV, whereas the output of the multiplier 
remains at ground potential. Secondary particles generated from the conversion 
dynode strike the first dynode surface causing an emission of secondary electrons. 
These electrons are then accelerated to the next dynode because it is held at a lower 
potential. They strike the second dynode causing the emission of more electrons. 
This process continues as the secondary electrons travel towards the ground 
potential. Thus a cascade of electrons is created and the final flow of electrons 
provides an electric current at the end of the electron multiplier that is then increased 
by conventional electronic amplification. 
6.2.5 Modes of LC/MS monitoring  
The first quadrupole, Q1, is operated in either a full-scan or SIM mode to 
select ions to pass on to the other analyzers in the system. The middle Q2 unit is 
flooded with a heavy inert gas, either krypton or xenon, and fragmentation is 
induced as the ions passed to Q2 from the first quadrupole  undergo thermal 
collision with the higher concentration of large molecules. The final analyzer, Q3, 
can also be selected for either full-scan or SIM mode operation. We have two 
operational modes for both Q1 and Q3, providing four possible experiments that are 
run with a triple-quad mass spectrometer.  
There are four possible modes of operation of the two analyzers:  
 Q1 scan/Q3 SIM, called daughter mode or precursor scanning. 
 Q1 SIM/Q3 scan, called parent mode or product scan. 
 Q1 scan/Q3 scan, referred to as neutral loss scanning mode. 
 Q1 SIM/Q3 SIM, referred to as multiple reaction monitoring (MRM) mode.  
Chapter 1 Introduction 
Dept. of Pharmaceutical Analysis 31 J.K.K. Nattraja College of Pharmacy 
6.2.5.1 Daughter Mode or Precursor Scanning 
SCAN/SIM mode operation lets us determine which primary fragments are 
related to each other. The first quadrupole is scanned over the mass range, and all 
fragments formed enter the collision cell and fragment to form secondary fragments. 
The third quadruple is parked at a specific mass/charge position and only primary 
fragments that break down to form this specific secondary m/z value will be detected. 
This common daughter ion points out interrelated primary fragments and helps us to 
understand which fragments are formed when a large primary fragment breaks down. 
In LC/MS we could store a TIC run of a peptide mixture for retention times and 
molecular-weight determination and then run Q3 parked at mass 79 and lay this 
chromatogram over the TIC to detect phosphorylated peptides present in the mixture. 
6.2.5.2 Parent Mode or Product Scan 
SIM/scan operations parks the first quadrupole analyzer at a specific mass, 
allowing only a single primary fragment to enter the collision cell where it 
fragments into secondary ions. The final quadrupole is run in full-scan mode, 
detecting all secondary product fragments formed from this single primary parent, 
again providing structural information by showing its breakdown products. This 
mode is commonly used in LC/MS to examine a molecular ion for its mass 
spectrometer fragments to provide structural identification. 
6.2.5.3 Neutral Loss Scanning Mode 
Scan/scan operation, or neutral loss mode, is a little more complicated since 
both analyzer quadrupoles will be scanned at the same time but with a preset mass 
offset.  
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When a primary fragment undergoes further fragmentation, it breaks into 
two pieces, a charged secondary fragment and a neutral molecule. What we are 
detecting in this mode are primaries that lose the same neutral molecule, such as 
carbon monoxide, water, or a vinyl compound, and therefore may be breaking down 
by the same fragmentation mode. The molecular mass of our suspected “neutral 
loss” is the value we assign to our scan offset between the two scanning quadrupole 
analyzers. All primary fragments separated in the first analyzer enter the collision 
cell and fragment. Only secondary fragments whose mass is exactly the neutral loss 
smaller than their primary fragment are detected after the final quadrupole and show 
up in the display of the scanning chromatogram. Any primary fragment that breaks 
down by forming a neutral molecule that has a mass different from the offset mass 
will not be selected by the second analyzer and enter the detector. 
6.2.5.4 Multiple Reaction Monitoring (MRM) Mode 
SIM/SIM operation is designed to analyze specific components of very 
impure mixtures definitively without having to purify them completely. They can be 
detected at a very high sensitivity since both analyzers are parked at different 
specific single m/z values, and a greater number of scans can be summed in 
determining their position. Nature makes very complex mixtures that cannot always 
be separated completely either though extractions or by chromatography. We 
examine a chromatographic peak in which we expect a specific compound to appear 
by using the first quadrupole to separate a primary fragment characteristic of the 
compound of interest, pass it into the collision cell, and use the final quadrupole to 
identify it by looking for only one of its specific daughter ions. (Edmond and 
Hoffmann 2004). 
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We can identify and quantitate each targeted compound in a mixture, even if 
the chromatographic peaks that contain them are contaminated. For each compound 
to be analyzed, we select an individual primary and secondary fragment on a time 
basis, in step with their expected chromatographic retention time.  
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LITERATURE REVIEW 
 Mary Ellen Sweeney, Rebecca R. Johnson, Expert Opinion, Drug 
evaluation, Ezetimibe: an update on the mechanism of action, 
pharmacokinetics and recent clinical trials, 2007, (441-450). 
Elevated serum cholesterol is a known risk factor for the development of 
coronary artery disease. Circulating cholesterol is a product of both cholesterol 
absorption from the gut and cellular cholesterol production. Ezetimibe is a novel 
cholesterol-lowering drug that acts at the brush border of the small intestine. Recent 
studies have further identified the molecular target as the Niemann-Pick C1-like 
transporter. Ezetimibe blocks the absorption of dietary and biliray sterols resulting in 
intracellular cholesterol depletion. Clinical studies have demonstrated beneficial 
improvements in the lipid profile with Ezetimibe as monotherapy, but dramatic 
effects are seen when Ezetimibe is combined with other lipid-lowering drugs, 
particularly 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). 
Combination studies of Ezetimibe with statins, bile acid sequestrants, fenofibrate 
and niacin all demonstrate significant total and low density lipoprotein cholesterol 
lowering. An excellent safety and tolerability profile combined with once-daily 
dosing make this attractive adjunct therapy for the treatment of 
hypercholesterolemia. 
 Unnam Seshachalam, Chandrasekhar B. Kothapally, HPLC Analysis 
for Simultaneous Determination of Atorvastatin and Ezetimibe in 
Pharmaceutical Formulations, Journal of Liquid Chromatography and Related 
Technologies, (2008) 32:5, 714-721. 
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A simple, isocratic, and sensitive reverse phase high performance liquid 
chromatographic(RP-LC) method has been developed, for the first time, for 
quantitative determination of Atorvastatin and Ezetimibe in pharmaceutical 
formulations, Atorvastatin and Ezetimibe were chromatographed using 0.01 M 
ammonium acetate buffer (pH: 3.0): Acetonitrile (50:50 v/v) as mobile phase. The 
detection was monitored at 254nm. The retention time of ezetimibe and Atorvastatin 
were 15.50 and 19.30 respectively. The linearity of the method was studied over the 
concentration range of 4-400 µg/mL for Atorvastatin and 5-500 µg/mL for 
Ezetimibe. The limit of detection for Atorvastatin and Ezetimibe were found as 
1.25µg/mL and 1.48µg/mL, respectively. The proposed method was applied for the 
quantitative determination of Atorvastatin and Ezetimibe in commercial 
combination formulations. 
 Stefan Ostwald, Eberhard Scheuch, Ingolf Cascorbi, Werner Siegmund, 
A LC-MS/MS method to quantify the novel cholesterol lowering drug 
Ezetimibe in human serum, urine and feces in healthy subjects genotyped for 
SLCO1B1, Journal of Chromatography B, 830(2006), 143-150. 
Ezetimibe is a novel cholesterol lowering drug which disposition is not fully 
understood in man. We developed a selective and high-sensitive assay to measure 
serum concentration-time profiles, renal and fecal elimination of ezetimibe in 
pharmacokinetic studies. Ezetimibe glucuronide, the major metabolite of ezetimibe 
was demonstrated by enzymatic degradation to the parent compound. Ezetimibe was 
measured after extraction with tert-butyl ether using 4-hydroxychalcone as internal 
standard and liquid chromatography coupled with an APCI interface with tandem 
mass spectrometry for detection. The chromatography (column XTerra MS C18, 2.1 
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mm x 100mm, particle size 3.5µm) was done isocratically with Acetonitrile: water: 
60:40, flow rate 200µL/min. The MS/MS analysis was performed in the negative ion 
mode. The validation ranges for Ezetimibe were as follow serum 0.00001-
0.015µg/mL and 0.001-0.2 µg/mL; urine and fecal homogenate 0.025-10 µg/mL and 
0.1-20 µg/mL, respectively. The assay was successfully applied to measure 
ezetimibe disposition in two subjects genotyped for the hepatic uptake transporter 
SLCO1B1. 
 Oliveira P. R., Brum Junior L., Fronza M., Bernardi L. S., Masiero M. 
K., Dalmora S. L., Development and Validation of a Liquid chromatography-
Tandem Mass Spectrometry Method for the determination of Ezetimibe in 
Human Plasma and Pharmaceutical Formulations, Chromatographia 2006, 63. 
An Analytical method based on liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) was developed and validated for the determination of 
ezetimibe in human plasma. Ezetimibe and Etroricoxib (Internal Standard) were 
extracted from the plasma by liquid–liquid extraction and separated on a C18 
analytical column (50 x 3.0 mm ID) with Acetonitrile: water: 85:15 as mobile phase. 
Detection was carried out by positive electro spray ionization in multiple-reaction 
monitoring (MRM) mode. The chromatographic separation was obtained within 2.0 
min and was linear in the concentration range of 0.25-20ng/mL for free ezetimibe 
and of 1-300ng/mL for total ezetimibe. The mean extraction recoveries for free 
ezetimibe and total ezetimibe from plasma were 96.14 and 64.11% respectively. 
Method validation investigated parameters such as linearity, precision accuracy, 
specificity and stability, giving results within the acceptable range. The proposed 
method was successfully applied to the quantification of ezetimibe and its 
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glucuronide in human plasma to support clinical and pharmacokinetics studies. 
Moreover, the method was used for the quality control analysis of pharmaceutical 
dosage forms. 
 Hossein Danafar, Mehrdad Hamidi, a Rapid and Sensitive LC-MS 
Method for determination of Ezetimibe concentration in Human Plasma: 
Application to a Bioequivalence Study, Chromatographia (2013) 76:1667-1675. 
A Selective and highly sensitive high performance liquid chromatography-
electrospray ionization mass spectrometry method has been developed for 
determination of ezetimibe in human plasma.  Ezetimibe was extracted from plasma 
with ethyl acetate followed by evaporation of the organic layer and then, 
reconstitution of the residue in mobile phase before injection to chromatograph. The 
mobile phase constituted of Acetonitrile-ammonium acetate (10mM. pH 3.0), 75:25. 
An aliquot of 10µL was chromatographically analyzed on a pre-packed Zorabax 
XDB-ODS C18 column (2.1 x 100mm, 3.5 micron). Detection of analytes was 
achieved by mass spectrometry with atmospheric pressure chemical ionization 
(APCI) interface in the negative ion mode operated under the multiple-reaction 
monitoring mode (MRM). Standard curve were linear over the wide ezetimibe 
concentration range of 0.005-30.0ng/mL with acceptable accuracy and precision. 
The limit of detection was 0.02ng/mL. The validated LC-APCI-MS method has 
been successfully throughout a bioequivalence study on an ezetimibe generic 
product in 24 healthy male volunteers. 
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 Shuijun Li, Gangyi Liu, Jingying Jia, Xiaochuan Li, Chen Yu, Liquid 
Chromatography-Negative ion Electrospray Tandem Mass Spectrometry for 
the Quantification of Ezetimibe in Human Plasma, Journal Of Pharmaceutical 
And Biomedical Analysis, 40 (2006)., 987-992. 
A simple, reliable and sensitive liquid-liquid chromatography-tandem 
spectrometry method (LC-MS/MS) was developed and validated for quantification 
of free and total ezetimibe in human plasma. The analyte and internal standard 
(Ezetimibe 13C6) were extracted by liquid-liquid extraction with methyl tert-butyl 
ether. The reversed-phase chromatographic separation was performed on a Capcell 
C18 column, and the plasma extract was eluted with a gradient consisting of 
Acetonitrile and 5mM ammonium acetate. The analyte was detected using negative 
ionization by multiple-reaction monitoring mode. The mass pair of 408.5      270.8 
and m/z 414.5    276.8 were used to detect ezetimibe and internal standard, 
respectively. The assay exhibited linear ranges from 0.02 to 20ng/mL for free 
ezetimibe and 0.25 to 250ng/mL for total ezetimibe in human plasma. Acceptable 
precision and accuracy were obtained for concentration of the calibration standard 
and quality control. The validated method was successfully used to analyze human 
plasma samples for application in a pharmacokinetic study. 
 Sistla R., Tata V. S. S. K., Kashyap Y. V., Chandrasekhar D., Diwan P. 
V., Development and validation of a reversed phase HPLC method for the 
determination of ezetimibe in Pharmaceutical dosage forms, Journal Of 
Pharmaceutical And Biomedical Analysis, 39 (2005), 517-522. 
Ezetimibe belongs to a group of selective and very effective 2-azetidone 
cholesterol absorption inhibitors that act on the level of cholesterol entry into 
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enterocytes. A rapid, specific reversed-phase HPLC method has been developed for 
assaying ezetimibe in pharmaceutical dosage forms. The assay involved an isocratic 
elution of ezetimibe in Kromasil 100 C18 column using a mobile phase composition 
of water (pH 6.8, 0.05%, 1-heptane sulfonic acid) and Acetonitrile (30:70). The flow 
rate was 0.5mL/min and the analyte monitored at 232 nm. The method was 
successfully applied to estimate the amount of ezetimibe in tablets. 
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DRUG PROFILE 
DRUG NAME  
Ezetimibe 
CHEMICAL NAME  
((3R,4S)-1-(4-Fluorophenyl)-3-[(S)-3-(4-Fluorophenyl)-3-hydropropyl]-4-
(4hydrophenyl) azetidine-2-one) 
MOLECULAR STRUCTURE 
 
 
 
 
MOLECULAR FORMULA  
C24H21F2NO3 
MOLECULAR MASS  
409.43 g/mol 
PROPERTIES 
 Ezetimibe is an odorless white crystalline powder,  
 It having a bitter taste. 
 It is soluble in dilute acids, methanol and chloroform. 
 It is practically insoluble in water. 
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CATEGORY     
Anti-hyperlipidaemic 
CLINICAL PHARMACOLOGY 
Ezetimibe, a novel drug that acts by inhibiting intestinal absorption of 
cholesterol and phytosterols. It interferes with a specific CH transport protein NPC1L1 
in the intestinal mucosa and reduce absorption of both dietary and biliray CH. 
MECHANISM OF ACTION 
The mechanism of action is distinct from other potent lipid- lowering drug 
that acts in the gut. Ezetimibe is a potent inhibitor of cholesterol and phytosterols 
absorption in the small intestine, where both dietary and biliary cholesterol are 
available for absorption. However, its action is unique in that does not affect 
cholesterol micelle formation or increase bile acid secretion. It does not alter fat-
soluble vitamin and nutrient absorption. 
PHARMACOKINETICS  
1. ABSORBTION 
Peak plasma concentration of total Ezetimibe (free Ezetimibe + Ezetimibe 
Glucuronide) 1-2 Hr. Concomitant food administration has no effect on the rate or 
extent of oral bioavailability. Ingestion of a high fat meal significantly increased 
Cmax (by 44%) and decreased Tmax with no net change in AUC. This change was not 
considered clinically significant and can be taken without regard to meals or fat 
content. 
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2. DISTRIBUTION 
Highly bound to plasma protein (>93%) and not affected by chronic renal 
disease or moderate chronic liver failure. 
3. METABOLISM 
Extensive presystemic metabolism via intestinal uridine 5’diposphate-
glucuronosyl transferase enzyme to the active glucuronyl metabolite (Ezetimibe 
metabolite).Ezetimibe and its conjugate and then transported via the portal vessels to 
the liver where they undergo additional glucuronidation and subsequent bilary 
secretion into the intestine. Ezetimibe-glucuronide accounts for the 80-90% of drug 
in plasma. Plasma concentration time profiles exhibit multiple peaks, suggesting 
enterohepatic recirculation. The rate and extent can be affected by either intestinal or 
hepatic secretion via P-glycoprotein and multi drug resistance- associated protein 2. 
Ezetimibe is neither an inhibitor nor an inducer and only a minor substrate of 
common CYP iso-enzymes at clinically relevant doses. 
4. EXCRETION 
Bilary secretion into the intestine and subsequent excretion in the feces 
(78%) and urine (11%). The parent drug is the major component in feces and 
ezetimibe-glucuronide in urine. Following repeated dose administration, the 
estimated terminal elimination half-life is 16-31 hrs. Consistent with the elimination 
half life, a two folds accumulation is observed with repeated once-daily 
administration.  
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AIM AND PLAN OF WORK 
Studies to measure bioavailability and /or establish bioequivalence of 
product are important elements in support of orally administered Drug products in 
Investigational New Drug applications (INDs), New DRUG Applications (NDAs), 
Abbreviated New Drug application (ANDAs) and their supplements. The systemic 
exposure profile determined during clinical trial in IND period can serve as 
benchmark for subsequent BE studies. 
Mathematic analysis of plasma level v/s time curve permit estimation of half 
lives, absorption,  excretion rates, extent of absorption (area under curve ) and 
constants that are useful in determining the fate of a given Drug in an organism. 
Comparative bioavailability studies permit judgement as to the bioequivalence of 
Drugs. These determinations may in turn lead to important decision related to Drug 
product selection by pharmacists. 
Until recently, bio-availability (rate and extent of absorption of medicaments 
from drug delivery systems) of drugs was note emphasized. It was more or less 
assumed that if the physical and chemical integrities of a drug product were assured 
pharmacologic performance would be observed. It is now recognize that formulation 
factors can influence the biologic availability of a medicament from a dosage unit in 
mammalian systems. Consequently, it has become common practice to establish bio-
availability by measurement of blood levels of drugs following administration of 
dosage forms. 
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However it should be noted that neither bioavailability nor bioequivalence 
data could be generated without analytical methodology to accurate measure Drug in 
biological fluids. 
Methods of measuring drugs in biological media are increasingly important 
problems related to bio-availability and bio-equivalence, new drug development, 
drug abuse, clinical pharmacokinetics and drug research are highly dependent on 
accurately measured drugs in biological fluids. Bioavailability & bioequivalence, 
new Drug development, Drug abuse, clinical pharmacokinetics & Drug research are 
highly dependent on accurately measuring Drugs in biological fluids. 
For estimation of Drugs and its in vivo active metabolite present in 
biological fluid LC/MS/MS method is considered to be most suitable since it is a 
powerful and rugged method. It is also extremely specific, accurate, sensitive and 
rapid when compared to the other methods. 
Present experiment is to develop & validate a selective and sensitive method 
for the quantitative determination of Ezetimibe in human plasma using   LC-MS/MS 
technique.   
PLAN OF THE PRESENT STUDY IS AS FOLLOWS: 
1. Optimization of chromatographic conditions was proposed to be developed and 
optimized. 
 Selection of wavelength, 
 Selection of initial separation conditions,  
 Nature of the stationary phase, 
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 Nature of mobile phase (pH, peak modifier, solvent strength, ratio and flow 
rate), 
 Sensitivity 
2. The developed method were also proposed to be validated using the various 
validation parameters such as, 
 System Suitability Test 
 Selectivity 
 Carry over 
 Matrix Effect 
 Precision and Accuracy 
 Recovery 
 Dilution integrity 
 Ruggedness 
 Reinjection Reproducibility 
 Hemolysis Effect 
 Reagent Stability 
 Stabilities.
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MATERIALS AND METHODS 
DRUGS USED 
Standards Batch No./ Lot No. Manufacture Retest Date/ Date 
of Expiry 
Ezetimibe F028D0 USP Current Lot 
Ezetimibe D4 CRC-0213-094 Clearsynth 08May2019 
Ezetimibe Phenoxy 
Glucuronide 1424-095A8 TLC 14Jul2020 
 
CHEMICALS AND REAGENTS USED 
Materials and Reagent Grade Make/Suppliers 
Sodium Acetate Trihydrate AR CDH 
Sodium Hydroxide AR Merck 
β-Glucuronidase N/AP Sigma Aldrich 
Glacial Acetic Acid AR Merck 
Diethyl Ether AR Spectrochem 
Acetonitrile LCMS JT Baker 
L-Ascorbic Acid AR SDFCL 
Methanol LCMS JT Baker 
Ammonium Acetate AR Sigma Aldrich 
Water Milli-Q  Millipore 
K2EDTA Plasma N/AP Rajya Lakshmi Blood Bank 
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INSTRUMENT USED 
Name Model / Brand Make 
Multi Tube Vortexer 1401002 Tarson 
Vortex Shaker SPINIX Tarson 
Analytical Balance MSA225S-100-DA Sartorius 
Micro Balance MSA2.7S-000-DM Sartorius 
pH Meter Star A211 Thermo 
Centrifuge 5810 R Eppendorf 
Deep freezer (-65 ±10ºC) MDF-U74V-PE Panasonic 
Deep freezer (-20 ±5ºC) MDF-U731M-PE Panasonic 
Refrigerator MPR-514-PE Panasonic 
Refrigerator FKG 371 Vestfrost 
Auto Pipette RESEARCH PLUS Eppendorf 
Multipette M4 Eppendorf 
Milli Q water system ADVANTAGE A10 Millipore 
Ultra Sonicator Ultrasons-HD J.P. Selecta 
Nitrogen Evaporator Turbo Vap lv Biotage 
 
PREPARATION OF SOLUTIONS 
1. Ammonium Acetate Buffer (pH 4.0)  
 Weighed approximately 385.400 mg of ammonium acetate and transfered 
into a 1000.000 mL reagent bottle containing 1000.000 mL of water. Adjusted the 
pH to 4.0 using glacial acetic acid. Filtered, sonicate and labeled. 
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2. Diluent ( Methanol : Water :: 80:20 ) 
 Transferred 800.000 mL of Methanol into a regent bottle and added 200.000 
mL of Water mixed well and labeled. 
3. 0.5 M Sodium Acetate Buffer (pH 5.0)  
 Weighed approximately 6.804 g of sodium acetate trihydrate and transferred 
it into a 100.000 mL reagent bottle containing 100.000 mL of water, mixed well and 
adjusted the pH to 5.0 using glacial acetic acid and labeled. 
4. 1.00% L-ascorbic Acid 
 This solution is used as a diluent for the preparation of β-Glucuronide 
enzyme solution. 
 Weighed approximately about 1.000 g of L-Ascorbic acid and transferred it 
into a 100.000 mL reagent bottle containing 100.000 mL of water, mixed well and 
labeled. 
5. β-Glucuronidase Enzyme Solution(20000 IU/mL) 
 This solution is used for hydrolysis enzymatic reaction. 
 Prepared approximately about 20000 IU/mL of β-Glucuronidase Enzyme 
solution using 1.00% L-ascorbic Acid as a diluent, vortexed to mix and labeled. 
 Note: β-Glucuronidase Enzyme stock concentration may vary from lot to lot. 
 For Example: If stock concentration is 100000 IU/mL, take 2.000 mL 
enzyme from the stock and dilute it to 10.000 mL with 1.00 % L- Ascorbic Acid.  
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6. 0.1 N Sodium Hydroxide 
 Weighed approximately about 400.000 mg of sodium hydroxide and 
transferred it into a 100.000 mL reagent bottle containing 100.000 mL of water, 
mixed well and labeled. 
7. Mobile Phase (Acetonitrile: Buffer:: 75:25) 
 Transferred 750.000 mL of Acetonitrile into a 1000.000 mL reagent bottle and 
added 250.000 mL of 5mM Ammonium acetate buffer (pH 4.0) and mixed well, 
sonicate and labeled. 
8. Rinsing Solution 
 Acetonitrile shall be used as rinsing solution. 
PREPARATION OF EZETIMIBE CALIBRATION CURVE STANDARDS  
1. Stock Solution Preparation of Ezetimibe 
 Weighed accurately about 2.0198 mg of Ezetimibe working standard and 
transferred into 2.000 mL volumetric flask containing methanol and diluted up to the 
mark with the same. Calculate the actual concentration using amount weighed and 
purity of Ezetimibe. 
Stock conc. = 100xweightformulax)ml(,volumeTotal
1000xpercentassayx.wtmolecularx,taken.Wt
 
Weight taken 
(mg) 
Formula 
Weight 
Molecular 
Weight Assay % 
Total 
volume, (mL) 
Conc. 
ng/mL 
2.0198 409.43 409.43 99.70 2.000 1006870.300 
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2. Preparation of Ezetimibe Intermediate Solution1 (100687.030 ng/mL) 
 Pipette out 1.000 mL of Ezetimibe stock solution into 10.000 mL 
volumetric flask and diluted up to the mark with the diluent. 
3. Preparation of Ezetimibe Intermediate Solution2 (10068.703 ng/mL) 
 Pipette out 1.000 mL of intermediate stock solution1 into 10.000 mL 
volumetric flask and diluted up to the mark with the diluent. 
4. Preparation of Ezetimibe Intermediate Solution3   (1006.870 ng/mL) 
 Pipette out 1.000 mL of intermediate stock solution2 into 10.000 mL 
volumetric flask and diluted up to the mark with the diluent. 
5. Preparation of Working Solution of Ezetimibe  
 Working solution of different concentration of Ezetimibe was prepared 
using Volumetric Flask using different volumes of above intermediate solutions as 
described in following Table No. 1, for calibration curve standards. These 
intermediate solutions was diluted up to the mark with the diluent. 
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Table No. 1 Preparation of Working Solution for CC Standards 
Intermediate 
ID 
Volume of 
Intermediate (mL) 
Total 
Volume (mL) 
Working Solution 
Concentration of 
Ezetimibe 
(ng/mL) 
Working 
Solution ID 
Intermediate 
Solution3 0.250 10.000 25.000 WCS1 
Intermediate 
Solution3 0.500 10.000 50.000 WCS2 
Intermediate 
Solution2 0.625 10.000 625.000 WCS3 
Intermediate 
Solution2 1.250 10.000 1250.000 WCS4 
Intermediate 
Solution2 2.500 10.000 2500.000 WCS5 
Intermediate 
Solution1 0.500 10.000 5000.000 WCS6 
Intermediate 
Solution1 0.750 10.000 7500.000 WCS7 
Intermediate 
Solution1 1.000 10.000 10000.000 WCS8 
Intermediate 
Solution1 1.250 10.000 12500.000 WCS9 
Intermediate 
Solution1 0.625 10.000 6250.000 WSSS 
 
6. Preparation of Calibration Curve Standards 
Calibration curve standards shall consist of blank plasma, zero blank and 
non-zero calibration curve standards covering the expected range of concentrations 
of analyte. Stock dilutions shall be used for the preparation of different calibration 
curve standards and resulted concentrations of Ezetimibe in spiked plasma for 
different calibration curve standards is as described in Table No. 2.  
Note: For Blank plasma and Zero Blank samples, spike 2.00% of Diluent in place of 
working solution. 
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Table No. 2 Preparation of Calibration Curve Standards 
Working 
Solution ID 
Volume of 
Blank 
Plasma 
(mL) 
Working 
Solution 
Volume 
(mL) 
Final 
Volume 
(mL) 
Final 
Concentration of                   
Ezetimibe 
(ng/mL) 
Calibration 
Curve 
Standards ID 
WCS1 9.800 0.200 10.000 0.500 CS1 
WCS2 9.800 0.200 10.000 1.000 CS2 
WCS3 9.800 0.200 10.000 12.500 CS3 
WCS4 9.800 0.200 10.000 25.000 CS4 
WCS5 9.800 0.200 10.000 50.000 CS5 
WCS6 9.800 0.200 10.000 100.000 CS6 
WCS7 9.800 0.200 10.000 150.000 CS7 
WCS8 9.800 0.200 10.000 200.000 CS8 
WCS9 9.800 0.200 10.000 250.000 CS9 
WSSS 9.800 0.200 10.000 125.000 SSS 
 
PREPARATION OF EZETIMIBE QUALITY CONTROL SAMPLES 
1. Stock Solution Preparation of Ezetimibe 
Weighed accurately about 2.0792 mg of Ezetimibe working standard and transferred 
into 2.000 mL volumetric flask containing methanol and diluted up to the mark with 
the same. Calculate the actual concentration using amount weighed and purity of 
Ezetimibe. 
Stock conc. = 100xweightformulax)ml(,volumeTotal
1000xpercentassayx.wtmolecularx,taken.Wt
 
Weight taken 
(mg) 
Formula 
Weight 
Molecular 
Weight Assay % 
Total 
volume, (mL) 
Conc. 
ng/mL 
2.0792 409.43 409.43 99.70 2.000 1036481.200 
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2. Stock Solution Preparation of Ezetimibe Phenoxy Glucuronide 
  Weighed accurately about 2.9887 mg of Ezetimibe Phenoxy Glucuronide 
(Equivalent to 2.000 mg of Ezetimibe) and transferred into 2.000 mL volumetric 
flask containing methanol and diluted up to the mark with the same. Calculate the 
actual concentration using amount weighed and purity of Ezetimibe. 
Stock conc. = 100xweightformulax)ml(,volumeTotal
1000xpercentassayx.wtmolecularx,taken.Wt
 
Weight taken 
(mg) 
Formula 
Weight 
Molecular 
Weight Assay % 
Total 
volume, (mL) 
Conc. 
ng/mL 
2.9887 585.56 409.43 97.90 2.000 1022923.790 
 
3. Preparation of Ezetimibe and Ezetimibe Phenoxy Glucuronide 
Intermediate Solution4 (102563.527 ng/mL) 
  Pipette out 0.200 mL of Ezetimibe stock solution and 0.800 mL of Ezetimibe 
Phenoxy Glucuronide stock solution into 10.000 mL volumetric flask and dilute up 
to the mark with the diluent. 
4. Preparation of Ezetimibe and Ezetimibe Phenoxy Glucuronide 
Intermediate Solution5 (10256.353 ng/mL) 
  Pipette out 1.000 mL of intermediate stock solution4 into 10.000 mL 
volumetric flask and dilute upto the mark with the diluent. 
5. Preparation of Ezetimibe and Ezetimibe Phenoxy Glucuronide Intermediate 
Solution6 (1025.635 ng/mL) 
  Pipette out 1.000 mL of intermediate stock solution5 into 10.000 mL 
volumetric flask and dilute upto the mark with the diluent. 
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Note: Subsequent intermediate dilutions shall be prepared from previous 
intermediate instead of respective stock solution. 
6. Preparation of Working Solution of Ezetimibe  
Working solution of different concentration of Ezetimibe shall be prepared 
using suitable container/Volumetric Flask using different volumes of above 
intermediate solutions as described in following Table No. 3, for quality control 
samples. These intermediate solutions shall be diluted up to the mark with the diluent. 
Table No. 3 Preparation of Working Solution for QC Samples 
Intermediate 
ID 
Volume of 
Intermediate 
(mL) 
Total 
Volume 
(mL) 
Working Solution 
Concentration of           
Ezetimibe (ng/mL) 
Working 
Solution ID 
Intermediate 
Solution6 0.250 10.000 25.000 WLLOQQC 
Intermediate 
Solution6 0.600 10.000 60.000 WLQC 
Intermediate 
Solution5 2.000 10.000 2000.000 WMQC1 
Intermediate 
Solution5 5.500 10.000 5500.000 WMQC 
Intermediate 
Solution4 1.000 10.000 10000.000 WHQC 
Intermediate 
Solution4 4.000 10.000 40000.000 WDIQC 
 
Diluent: Methanol: Water (80: 20 v/v) 
7. Preparation of Quality Control Samples 
Quality control samples shall be prepared in screened blank/ pooled plasma with 
stock dilutions of known concentrations. The QC samples shall be prepared in 
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replicates at each different concentration levels i.e. LLOQ QC, LQC, MQC1, MQC, 
HQC, and DIQC). Stock dilutions shall be used for the preparation of different 
concentration levels of QC and resulted concentrations of Ezetimibe in spiked 
plasma for different QC samples as described in Table no. 4. 
TABLE No. 4 Preparation of Quality Control Samples 
Working 
Solution ID 
Volume of 
Blank 
Plasma 
(mL) 
Working 
Solution 
Volume 
(mL) 
Final 
Volume 
(mL) 
Final 
Concentration 
of Ezetimibe 
(ng/mL) 
Quality 
Control ID 
WLLOQQC 9.800 0.200 10.000 0.500 LLOQQC 
WLQC 9.800 0.200 10.000 1.200 LQC 
WMQC1 9.800 0.200 10.000 40.000 MQC1 
WMQC 9.800 0.200 10.000 110.000 MQC 
WHQC 9.800 0.200 10.000 200.000 HQC 
WDIQC 9.800 0.200 10.000 800.000 DIQC 
 
Note:   
1. QC samples shall be prepared containing both Ezetimibe Phenoxy Glucuronide 
and Ezetimibe to mimic the study sample analysis requirement as the study 
samples will contain both Ezetimibe Phenoxy Glucuronide and Ezetimibe. The 
QC samples shall be prepared in the proportion of 80: 20 where 80% of 
Ezetimibe Phenoxy Glucuronide and 20% of Ezetimibe. 
2. As spiking solutions of calibration curve standard are prepared using Ezetimibe 
only and spiking solutions of quality control samples were prepared using 
Ezetimibe and Ezetimibe Phenoxy Glucuronide, spiking solution check 
experiment shall be performed in extracted medium (using spiking solution spiked 
into water (Milli Q/HPLC Grade). 
Chapter 5 Materials and Methods 
Dept. of Pharmaceutical Analysis 56 J.K.K. Nattraja College of Pharmacy 
PREPARATION OF EZETIMIBE D4 
1. Preparation of Ezetimibe D4 Internal Standard Stock Solution  
  Weighed about 2.000 mg of Ezetimibe-D4 working standard and transferred 
into 2.000 mL volumetric flask containing methanol and diluted up to the mark with 
the same. Calculate the actual concentration using amount weighed and purity.  
2. Preparation of Ezetimibe-D4 Internal Standard Intermediate Solution 
(10000.000 ng/mL) 
  Pipette out 0.100 mL of Ezetimibe-D4 stock solution into 10.000 mL 
volumetric flask and dilute up to the mark with the diluent. 
3. Preparation of Ezetimibe-D4 Internal Standard Working Solution (50.000 
ng/mL) 
  Pipette out 0.500 mL of Ezetimibe-D4 internal standard intermediate 
solution into 100.000 mL volumetric flask and dilute up to the mark with the diluent. 
PREPARATION OF EXTRACTED AQUEOUS LINEARITY SOLUTION 
The working solution of calibration curve standards and quality control 
samples shall be spiked in water and extracted as per extraction procedure. 
PREPARATION OF SYSTEM SUITABILITY SOLUTION (SSS) 
1. Aqueous SSS 
  Pipette out 4.000 µL of working solution WSSS- (6250.000 ng/mL for 
Ezetimibe), add 50.000 µL of Internal Standard Working Solution WIS- (50.000 
ng/mL each of Ezetimibe D4) and add 146.000 µL of mobile phase and vortex it.  
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2. Extracted SSS 
  SSS sample will be processed as per extraction procedure and will be used as 
extracted system suitability sample for system suitability test. 
Note: Dilutions can be adjusted in proportion during solution preparation and 
spiking however final concentration should remain same. 
EVALUATION 
The standard curves were constructed from the peak area ratio (P.A.R.) of 
drug / IS using linear regression   y = ax + b with 1/x² weighing. 
Drug concentrations (ng/mL) for QCs in a batch calculated by interpolating 
the peak area ratios from the corresponding standard curve.The measured peak area 
ratios of the QC samples were converted into concentration. 
Using the following equation,                    
Drug concentration            =  
a
b)IS/Drug(.R.A.P −
 
Where      
a = Slope of the corresponding standard curve, 
           b = Intercept of the corresponding standard curve. 
The concentrations were reported in nanogram per milliliter plasma. 
TUNING OF DRUG AND INTERNAL STANDARD  
For drug and IS the tunning was done manually using Methanol: water 
(50:50) with syringe needle. 
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First scanning was performed for Q1 to get mass of the parent ion. Then this 
ion goes to Q2 where fragmentation takes place by collision energy leads to the 
formation of daughter ions. This daughter ion was scanned in Q3. 
Formation of ions and traveling from one quadrapole to another all activities 
performed by setting different potential. C.E, C.X.P, E.P and DP. 
INSTRUMENT SETTING :( API-4000) 
1. For Ezetimibe 
Scan 
Type 
Polarity 
Q1 
Mass 
(amu) 
Q3 
Mass 
(amu) 
Dwell 
(msec) 
Parameter 
DP EP CE CXP 
MRM Negative 408.100 271.000 200 -57 -10 -22 -10 
 
2. For Ezetimibe D4 
Scan 
Type 
Polarity 
Q1 
Mass 
(amu) 
Q3 
Mass 
(amu) 
Dwell 
(msec) 
Parameter 
DP EP CE CXP 
MRM Negative 412.100 275.000 200 -55 -10 -22 -15 
 
INSTRUMENT PARAMETERS 
CUR CAD GS1 GS2 TEM IS 
20 5 50 50 500 -4500 
 
For this particular project tuning was performed in negative mode for analyte and for 
internal standard.  
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PRETREATMENT OF BIOLOGICAL SAMPLE 
In bio-analysis the method development step additionally require the 
extraction trial in order to recover the analyte and internal standard from highly 
complicated biological matrix one should have knowledge about the nature of the 
Drug, its molecular weight, polarity, pKa, ionic character and the solubility 
parameter. 
Selection of internal standard should be on the basis of structural similarity, 
physicochemical properties related to the analyte to be quantified. 
In initial stages of method development our focus is on achieving our LLOQ 
level with precision and accuracy and checking for interference at the retention time 
of analyte and internal standard. 
Method development trials involve a lot of exercises based on chemistry of 
molecule and efficiency of our extraction procedure in order to achieve good results. 
Optimization of mobile phase, buffer, and column are essential part of method 
development.  
The peak shape, retention time of analyte and internal standard, column, flow 
rate are optimized by making aqueous solution of drug and internal standard in a set 
of different mobile phase compositions. 
SAMPLE PROCESSING 
Prior to starting the extraction procedure, ensure that the required reagent 
have been prepared and are within the usage period.  
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Retrieve one CC standard and/or QC samples and/ or spiked samples from 
the deep freezer and allow to thaw at room temperature. 
Vortex the thawed samples to ensure complete mixing of content. 
Extract Plasma and Aqueous samples by Liquid-Liquid extraction method as 
described below: 
 Place an appropriate number of RIA vial in a rack. 
 Add 50.000 µL of WIS (50.000 ng/mL) into each tube except plasma blank. 
 Aliquot 0.200 mL plasma sample into previously labeled tube and vortex it. 
 Add 250.000 µL of 0.5 M sodium acetate (pH 5.0) and vortex it. 
 Add 50.000 µL of enzyme solution (20000 IU/mL) and vortex it. 
 Incubate the samples in water bath for 30 min at 50ºC. 
 Add 250.000 µL of 0.1 N sodium hydroxide and vortex. 
 Add 3.000 mL of Diethyl ether. 
 Vortex the sample at 2500 RPM for 5 min in multi-tube vortexer. 
 Centrifuge at 10ºC for 5 min at 4000 RPM. 
 Flash Freeze the plasma layer and transfer the organic layer in to pre-labeled 
tubes. 
 Evaporate till dryness under nitrogen steam at 40ºC 
 Reconstitute with 200.000 µL of Mobile phase and vortex. 
 Transfer the contents to Autosampler vials. 
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METHOD DEVELOPMENT TRAILS 
Table No. 5 Method Development Trails 
Run 
No 
Extraction 
Procedure 
Chromatographic 
Conditions Change Mode Observations 
1 
SPE Method 
with 
Oasis ®  HLB 
3cc 60mg SPE 
cartilage 
Column:Hypurity 
C18,50X4.6 
Flow rate:0.6ml 
Inj Volm:10µl 
RT :5Min 
MP:ACN:2mM 
Amm.Acetate(70:30) 
NOT 
APPLICABLE 
Area of drug and 
analyte & IS 
found to be 
satisfactory. 
2 
SPE Method 
with 
Oasis ®  HLB 
3cc 60mg SPE 
cartilage 
Column:Hypurity 
C18,50X4.6 
Flow rate:0.6ml 
Inj Volm:5µl 
RT :2.2Min 
MP:ACN:2mM 
Amm.Acetate(90:10) 
100µl 5% Ortho 
phosphoric acid 
was added during 
sample processing 
and run time 
changed 5min to 
2.2min 
Recovery found to 
be more & 
chromatography 
found to be 
satisfactory. 
3 
LLE with 
tertiary butyl 
methyl ether’ 
Column:Hypurity C18, 
50X4.6 
Flow rate:0.6ml 
Inj Volm:10µl 
RT  :5Min 
MP: MeOH:2mM 
Ammonium 
Acetate(70:30) 
Extraction metod 
was  changed from 
SPE to LLE 
Results are within 
the acceptable 
criteria. but poor 
chromatograms 
was 
Observed. 
4 LLE  with 
ethyl acetate 
Column: Hypurity C18, 
50X4.6 
Flow rate:0.6ml 
Inj Volm:10µl 
RT :5Min 
MP: MeOH:2mM 
Ammonium 
Acetate(70:30) 
Tertiary butyl 
methyl ether is 
replaced with ethyl 
acetate 
Area of drug and 
analyte & IS 
found to be 
satisfactory. And 
Chromatography 
need to  develop. 
5 LLE with Diethyl ether 
Column:Gemini, 
C18,150X 
Flow rate:0.5ml 
Inj Volm:10µl 
RT :5Min 
MP:ACN:5mM 
Amm.Acetate(75:25) 
Ethyl acetate is 
replaced with 
diethyl ether 
Recover of analyte 
and IS is 
satisfactory, 
Chromatography 
is satisfactory and 
fixed as final 
extraction method 
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SELECTED CHROMATOGRAPHIC CONDITION    
Column : Gemini, C18,  110A˚, 5µm, 150 * 3 mm 
Buffer  : 5 mM Ammonium Acetate (pH 4.0) 
Mobile phase               : Pump A: Buffer, Pump B: Acetonitrile 
In the ratio. 25:75 
Flow rate : 0.500 mL/minute  
Injection volume : 10.000 µL 
Auto sampler temperature        : 10°C 
Column Temperature                : 35°C 
Rinsing solution                        : Acetonitrile  
Run time : 3.00 minutes  
Retention time                          : Ezetimibe  at around 1.96 minutes 
Ezetimibe-D4
 
at around 1.94 minutes. 
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RESULT AND DISCUSSION 
SYSTEM SUITABILITY TEST  
This test was performed in order to check the suitability of the system with 
optimized final condition and to maintain performance of the system reproducibility 
in changing environment. The percent co-efficient of variation for peak area ratio of 
analyte to internal standard and for retention time were under the acceptance criteria 
i.e. % C.V was less than 5 % for LC-MS/MS based procedures.  Retention time for 
drug and IS was around 1.96 min and 1.94 min respectively. 
Table No. 6 System Suitability Test 
S. No. Analyte Area IS area Area ratio RT of analyte RT of IS 
1 859870 80106 10.734 1.93 1.92 
2 866907 80724 10.739 1.93 1.92 
3 887991 83353 10.653 1.93 1.92 
4 885149 82373 10.746 1.93 1.92 
5 875909 82372 10.634 1.93 1.92 
6 867605 81671 10.623 1.93 1.92 
Mean 873905.2 81766.5 10.6882 1.930 1.920 
S.D± 11086.05 1192.03 0.05735 0.0000 0.0000 
%CV 1.27 1.46 0.54 0.00 0.00 
 
SELECTIVITY 
The selectivity is generally defined as the lack of interfering peaks at the 
retention time of the assayed drug and the internal standard in the chromatograms. 
Six lots of human blank plasma (four normal, one lipemic and one hemolysed) 
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containing K2EDTA as an anticoagulant was evaluated for their selectivity and no 
interference was observed at the retention time of Ezetimibe and Ezetimibe D4 
(Internal Standard) in any of the human blank plasma lots. 
Acceptance Criteria 
1. % Responses of interfering peaks at the RT of analyte should be < 20% 
response of the analyte in LLOQ. 
2. % Responses of interfering peaks at the RT of IS should be < 5% response of 
the IS in LLOQ. 
TABLE No: 7 Selectivity 
Batch No./ Lot 
No. 
Analyte 
Response 
% 
Interference at 
RT of Analyte 
IS Response % Interference at 
RT of IS 
Blank LLOQ Blank LLOQ 
RCT/ML-001 81 4731 1.71 0 83892 0.00 
RCT/ML-002 80 4709 1.70 0 88530 0.00 
RCT/ML-003 213 4698 4.53 0 77959 0.00 
RCT/ML-004 0 3925 0.00 0 75396 0.00 
LP021 0 5016 0.00 0 92684 0.00 
HP030 232 5033 4.61 231 89807 0.26 
 
CARRY OVER 
 The experiment was performed to check the carryover of the assay method 
and carryover of the instrument. The carry over experiment was performed by 
injecting extracted samples in the following sequence: Blank, LLOQ samples in 
duplicate, ULOQ samples in duplicate and Blank (Duplicate injection from same 
vial). Both the LLOQ samples were used for the evaluation of carry over effect. 
From results it can be concluded that, there was no carry-over or contamination 
observed at the retention time of Ezetimibe and Ezetimibe D4 (Internal Standard). 
Chapter 6 Result and Discussion 
Dept. of Pharmaceutical Analysis 65 J.K.K. Nattraja College of Pharmacy 
Acceptance Criteria 
1. Response of interfering peaks at the retention time of analyte in the blank 
sample injected after ULOQ sample should be within 20 % of the mean response of 
the LLOQ sample. 
2. Response of interfering peaks at the retention time of internal standard in the 
blank sample injected after ULOQ sample should be within 5 % of the mean 
response of the LLOQ sample. 
Table No. 8 Carryover 
Sample ID Analyte Response 
Mean 
Response of  
Analyte at 
LLOQ 
IS 
Response 
Mean 
Response 
of IS at 
LLOQ 
% Carryover 
Analyte IS 
BLANK-01 60 
4122.5 
337 
76075.5 
N/AP N/AP 
LLOQ-01 4075 72373 
LLOQ-02 4170 79778 
ULOQ-01 2234166 83799 
ULOQ-02 2184166 82102 
BLANK-01 0 354 0.00 0.47 
BLANK-01 52 306 1.26 0.40 
 
MATRIX EFFECT 
 Matrix factor is the quantitative measure of the matrix effect due to suppression 
or enhancement of ionization in mass spectrometric detector. Matrix effect was 
evaluated through matrix factor, which is calculated by comparing area response in 
presence of matrix ions with mean area response in absence of matrix ions. 
1. Area response in absence of matrix ion: 
 The extracted aqueous quality control samples were prepared at two distinct 
levels of LQC and HQC, by spiking the appropriate volume of respective spiking 
solutions into water and processed as per extraction procedure. Six replicate of low 
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and high level of quality control samples were are prepared. The mean area response 
of these six injections was considered as area response in absence of matrix ions. 
2. Area response in presence of matrix ion: 
 Six lots of K2EDTA blank plasma samples (four normal, one hemolysed and 
one lipemic) were taken. Two replicates from six lots of K2EDTA blank plasma 
samples along with six replicates of low and high level of quality control samples 
were prepared in water and processed as per extraction procedure. 
 Thereafter, quality control samples were prepared at two distinct levels of 
LQC & HQC by reconstituting the above processed blank samples with respective 
processed aqueous quality control samples.  
 Single injection was given from each lot and obtained area response at low 
and high level of quality control samples was considered as area response in 
presence of matrix ions. The matrix factor was derived using below mentioned 
equation for analyte and internal standard. 
 
 
The IS normalized matrix factor was derived using below mentioned equation. 
 
 
Acceptance Criteria:  
The % CV for IS normalized matrix factors in six lots should be within 15% 
at LQC and HQC level. 
Matrix factor = 
Peak area in presence of matrix ions 
Mean peak area in absence of matrix ions 
IS Normalized MF = 
Matrix factor of analyte 
Matrix factor of internal standard 
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Table No. 9 Matrix Effect 
PEAK AREA IN ABSENCE OF MATRIX IONS 
S. No LQC HQC Analyte Internal Standard Analyte Internal Standard 
1 9390 97476 1635886 103609 
2 7871 79079 1435663 85482 
3 10256 102990 2000963 122192 
4 10194 103758 1975642 119796 
5 8280 85501 1622051 98392 
6 7204 80496 1965879 124131 
Mean 8865.8 91550.0 1772680.7 108933.7 
SD 1270.11 11219.03 239004.06 15583.27 
% CV 14.33 12.25 13.48 14.31 
PEAK AREA IN PRESENCE OF MATRIX IONS 
Blank Matrix 
Batch / Lots No. 
LQC HQC 
Peak area Matrix factor IS 
Normalized 
MF 
Peak area Matrix factor IS 
Normalized 
MF Analyte 
Internal 
Standard Analyte 
Internal 
Standard Analyte 
Internal 
Standard Analyte 
Internal 
Standard 
RCT/ML-001 6596 66851 0.74 0.73 1.02 1390965 88620 0.78 0.81 0.96 
RCT/ML-002 5586 62724 0.63 0.69 0.92 1019546 68281 0.58 0.63 0.92 
RCT/ML-003 5830 55485 0.66 0.61 1.09 1033654 67095 0.58 0.62 0.95 
RCT/ML-004 8618 83843 0.97 0.92 1.06 893356 55829 0.50 0.51 0.98 
LP021 6681 67911 0.75 0.74 1.02 914633 58185 0.52 0.53 0.97 
HP030 6996 63681 0.79 0.70 1.13 1236917 71767 0.70 0.66 1.06 
Mean 1.039 Mean 0.973 
SD 0.0734 SD 0.0478 
% CV 7.06 % CV 4.91 
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PRECISION AND ACCURACY 
 Precision and accuracy of analyte was determined for LLOQ QC, LQC, 
MQC1, MQC and HQC samples in the biological matrix, based on the expected range. 
Precision 
Precision of the assay was measured by the percent coefficient of variance 
over the concentration range of lower limit of quantification, low, medium and high 
quality control samples of analyte during the course of the validation.  
Within-batch precision (Intra-day precision) 1.37 % to 4.85 %. 
Between-batch precision (Inter-day precision) 1.79 % to 6.84 %. 
 
Accuracy 
Accuracy of the assay was defined as the absolute value of the ratio of the 
mean back-calculated values of the quality control samples to their respective 
nominal values, expressed in percentage.  
Within-batch accuracy (Intra-day accuracy) 84.34 % to 99.96 %. 
Between-batch accuracy (Inter-day accuracy) 93.27 % to 99.14 %. 
 
Acceptance Criteria for Quality Control Samples    
1. Accuracy of at least 50 % of QC samples at each level and at least 67 % of total 
QC samples should be within or equal to ± 15 % of their respective nominal 
concentration except LLOQQC, for which it should be within or equal to ± 20 % 
of the nominal concentration.  
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2. The precision (% CV) determined at each QC level should be within or equal to 
15 %, except LLOQQC, for which it should be within or equal to 20 %. 
3. Intraday (within run) and inter day (between run) accuracy should be within or 
equal to ± 20 % for LLOQQC, and for other quality control samples accuracy 
should be within or equal to ± 15 %.   
4. Intraday (within run) and inter day (between run) precision should be within or 
equal to 20 % for LLOQ QC, and for other quality control samples precision 
should be within or equal to 15 %. 
Table No. 10: Within and Between batch Precision and Accuracy 
Quality Control ID LLOQQC LQC MQC1 MQC HQC 
Nominal Concentration 
ng/mL 0.513 1.231 41.025 112.820 205.127 
Acceptance Range 
0.410 1.046 34.871 95.897 174.358 
0.616 1.416 47.179 129.743 235.896 
Back Calculated Concentration (ng/mL) 
P and A-01 
1 0.466 1.193 39.813 111.198 201.613 
2 0.410 1.154 40.724 109.611 194.748 
3 0.445 1.177 42.421 114.431 202.518 
4 0.413 1.177 41.062 112.810 204.386 
5 0.435 1.153 41.730 117.418 199.569 
6 0.427 1.183 39.653 111.163 193.098 
Mean 0.4327 1.1728 40.9005 112.7718 199.3220 
±SD 0.02098 0.01608 1.07667 2.80704 4.49061 
Precision (%CV) 4.85 1.37 2.63 2.49 2.25 
Accuracy (%) 84.34 95.27 99.70 99.96 97.17 
P and A-02 
1 0.495 1.274 40.136 115.159 203.791 
2 0.484 1.261 41.325 109.041 195.958 
3 0.482 1.183 39.402 108.303 201.843 
4 0.478 1.174 40.563 109.631 202.259 
5 0.505 1.177 38.491 114.282 206.139 
6 0.487 1.251 40.429 116.344 206.901 
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Quality Control ID LLOQQC LQC MQC1 MQC HQC 
Nominal Concentration 
ng/mL 0.513 1.231 41.025 112.820 205.127 
Acceptance Range 
0.410 1.046 34.871 95.897 174.358 
0.616 1.416 47.179 129.743 235.896 
Back Calculated Concentration (ng/mL) 
Mean 0.4885 1.2200 40.0577 112.1267 202.8152 
±SD 0.00989 0.04667 0.98893 3.52126 3.92350 
Precision (%CV) 2.03 3.83 2.47 3.14 1.93 
Accuracy (%) 95.22 99.11 97.64 99.39 98.87 
P and A-03 
1 0.491 1.191 40.917 108.927 199.146 
2 0.474 1.236 40.501 111.092 199.622 
3 0.478 1.252 39.555 109.423 202.257 
4 0.484 1.303 39.050 112.421 198.171 
5 0.468 1.203 40.491 109.795 195.274 
6 0.481 1.224 41.420 106.100 200.287 
Mean 0.4793 1.2348 40.3223 109.6263 199.1262 
±SD 0.00799 0.03999 0.87481 2.14253 2.33013 
Precision (%CV) 1.67 3.24 2.17 1.95 1.17 
Accuracy (%) 93.44 100.31 98.29 97.17 97.07 
P and A-04 
1 0.512 1.278 39.146 109.081 197.489 
2 0.506 1.244 41.423 111.654 203.521 
3 0.527 1.250 40.271 110.580 196.776 
4 0.534 1.239 39.819 106.853 202.555 
5 0.494 1.250 40.513 110.605 198.393 
6 0.508 1.264 39.955 110.780 200.465 
Mean 0.5135 1.2542 40.1878 109.9255 199.8665 
±SD 0.01464 0.01437 0.76341 1.71822 2.76827 
Precision (%CV) 2.85 1.15 1.90 1.56 1.39 
Accuracy (%) 100.10 101.88 97.96 97.43 97.44 
Global Statistics 
Quality Control ID LLOQQC LQC MQC1 MQC HQC 
Mean 0.4785 1.2205 40.3671 111.1126 200.2825 
±SD 0.03273 0.04318 0.93047 2.82462 3.58950 
Precision (%CV) 6.84 3.54 2.31 2.54 1.79 
Accuracy (%) 93.27 99.14 98.40 98.49 97.64 
 
Note: Attachment 02 includes representative chromatograms of P and A Batch. 
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RECOVERY 
 The recovery was determined by comparing the detector response of analyte 
at three distinct levels of extracted low medium and high quality control samples 
with detector response obtained from the recovery samples. Recovery samples were 
prepared by processing aqueous low, medium and high quality control samples. 
 Based on the results, it was concluded that recovery is precise for the 
analyte at all three QC levels. 
For Analyte 
 The mean % Absolute Recovery for analyte at low, medium and high 
quality control samples was 84.76 %, 84.37 % and 86.69 % respectively. The % CV 
for average of mean % Absolute Recoveries was 1.39 %. 
Acceptance Criteria  
 The % CV of % absolute recovery and overall % absolute recovery for 
analyte should be within 15% for each quality control. 
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Table No.11: Recovery of Ezetimibe 
 
Extracted 
LQC 
Un 
extracted 
LQC 
Extracted 
MQC 
Un 
extracted 
MQC 
Extracted 
HQC 
Un 
extracted 
HQC 
6349 8059 611480 727828 1251206 1499562 
6441 7019 610956 756142 1242757 1315405 
6407 8121 598332 693234 1322207 1384079 
6692 8099 646866 716286 1295590 1444124 
6932 7861 544556 749427 1204762 1378071 
7116 7961 653388 701992 1029404 1462504 
Mean 7853.3 Mean 724151.5 Mean 1413957.5 
SD 420.01 SD 25237.12 SD 67064.26 
% CV 5.35 % CV 3.49 % CV 4.74 
% Absolute Recovery 
LQC MQC HQC 
80.84 84.44 88.49 
82.02 84.37 87.89 
81.58 82.63 93.51 
85.21 89.33 91.63 
88.27 75.20 85.20 
90.61 90.23 72.80 
Mean 84.756 84.365 86.588 
SD 3.9925 5.4046 7.3565 
%CV 4.71 6.41 8.50 
Overall % Absolute Recovery 
Global Mean 85.2364 
Global SD 1.18698 
Global %CV 1.39 
 
For Internal standard 
 The mean % Absolute Recovery for internal standard at low, medium and 
high quality control samples was 86.56 %, 84.74 % and 86.92 % respectively. The 
% CV for average of mean of % Absolute Recoveries was 1.36 %.  
Acceptance Criteria 
 The % CV of % absolute recovery and overall % absolute recovery for 
internal standard should be within 15% for each quality control. 
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Table No. 12: Recovery of Ezetimibe D4 
 
Extracted 
LQC 
Un 
extracted 
LQC 
Extracted 
MQC 
Un 
extracted 
MQC 
Extracted 
HQC 
Un 
extracted 
HQC 
58863 72298 63491 75404 71628 87168 
61618 65004 62071 77731 74549 76123 
57657 73813 62414 69272 76678 80009 
60507 70387 66938 74729 76521 81963 
64532 72468 55707 78038 67859 79471 
66488 73097 67811 71381 58424 84965 
Mean 71177.8 Mean 74425.8 Mean 81616.5 
SD 3233.83 SD 3488.66 SD 3987.92 
% CV 4.54 % CV 4.69 % CV 4.89 
% Absolute Recovery 
LQC MQC HQC 
82.70 85.31 87.76 
86.57 83.40 91.34 
81.00 83.86 93.95 
85.01 89.94 93.76 
90.66 74.85 83.14 
93.41 91.11 71.58 
Mean 86.559 84.745 86.923 
SD 4.7320 5.8028 8.5541 
%CV 5.47 6.85 9.84 
                          Overall % Absolute Recovery 
Global Mean 86.0755 
Global SD 1.16666 
Global %CV 1.36 
 
DILUTION INTEGRITY 
 Dilution integrity for analyte was evaluated by preparing sample around 3 to 
4 times higher than the concentration of ULOQ. A sample of analyte having 
concentration of 820.508 ng/mL was prepared in human plasma and this was diluted 
with human blank plasma to 1/4 and 1/10 of the original concentration and analyzed 
using a set of  calibration curve standards. Precision and Accuracy of the dilution 
integrity samples for 1/4 and 1/10 dilutions were found within the acceptance 
criteria. 
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Precision 
for 1/4 dilution integrity samples 4.16 % 
for 1/10 dilution integrity samples 3.18 % 
Accuracy 
for 1/4 dilution integrity samples 96.21 % 
for 1/10 dilution integrity samples 100.85 %  
 
Table No. 13: Dilution Integrity 
Nominal Concentration 
(ng/mL) 820.508 820.508 
Acceptance Range 697.432 697.432 
943.584 943.584 
Dilution Factor Quality Control  (1/4) Quality Control  (1/10) 
Back Calculated 
Concentration (ng/mL) 
757.160 787.351 
786.564 804.611 
799.820 850.187 
798.195 835.155 
842.209 833.341 
752.507 854.461 
Mean 789.4092 827.5177 
SD 32.81241 26.34448 
% CV 4.16 3.18 
%Accuracy 96.21 100.85 
  
Ruggedness  
 To evaluate the ruggedness of method, one P and A batch was processed by 
different analyst and analyzed on different column (same type) with fresh reagents 
and solutions. The Ruggedness precision and accuracy batch was found to be within 
acceptance criteria. Based on the results, it was concluded that the method is rugged. 
within batch precision of quality control samples 1.21 % to 5.09 %, 
within batch accuracy of quality control samples 102.34 % to 107.08 % 
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Table No. 14 : Ruggedness 
Quality Control ID LLOQQC LQC MQC1 MQC HQC 
Nominal Concentration 
ng/mL 
0.513 1.231 41.025 112.820 205.127 
Acceptance Range 0.410 1.046 34.871 95.897 174.358 
0.616 1.416 47.179 129.743 235.896 
Back Calculated 
Concentration (ng/mL) 
0.571 1.352 42.484 116.040 213.061 
0.576 1.296 41.214 115.874 209.857 
0.510 1.316 42.509 116.556 207.939 
0.520 1.305 41.358 119.587 209.081 
0.543 1.292 43.278 115.928 227.448 
0.566 1.348 41.055 116.588 213.874 
Mean 0.5477 1.3182 41.9830 116.7622 213.5433 
±SD 0.02789 0.02603 0.89976 1.41836 7.19155 
Precision (%CV) 5.09 1.98 2.14 1.21 3.37 
Accuracy (%) 106.76 107.08 102.34 103.49 104.10 
 
Reinjection Reproducibility 
To estimate the reinjection reproducibility, samples of Precision and Accuracy-03 
was re-injected and it was found within acceptance criteria.  
Based on the results, the reinjection reproducibility was proved. 
within batch precision of quality control samples 2.17 % to 5.22%, 
within batch accuracy of quality control samples 94.48 % to 100.04 % 
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Table No. 15: Reinjection Reproducibility 
Nominal 
Concentration 
LLOQQC LQC MQC1 MQC HQC 
0.513 1.231 41.025 112.820 205.127 
Acceptance Range 0.410 1.046 34.871 95.897 174.358 
0.616 1.416 47.179 129.743 235.896 
Back Calculated 
Concentration 
(ng/mL) 
0.492 1.200 38.606 109.058 192.385 
0.502 1.247 40.936 110.722 191.783 
0.456 1.267 40.129 110.625 197.448 
0.478 1.221 39.181 106.252 202.220 
0.521 1.168 40.552 111.607 198.767 
0.459 1.286 39.991 114.758 201.564 
Mean 0.4847 1.2315 39.8992 110.5037 197.3612 
±SD 0.02530 0.04383 0.86608 2.81232 4.45273 
Precision (%CV) 5.22 3.56 2.17 2.55 2.26 
Accuracy (%) 94.48 100.04 97.26 97.95 96.21 
 
Hemolysis Effect 
Hemolysis effect has carried out to assess the impact on the accuracy and 
precision of the method, because of hemolysed matrix. Six replicates of LQC and 
HQC was prepared in one of the hemolysed matrix lot and analyzed against bulk 
spiked calibration standard. 
Based on the results, it was concluded that there is no hemolytic effect. 
within batch precision LQC: 3.44 % and HQC: 1.68 %, 
within batch accuracy LQC:  98.06 % and HQC: 95.76 % 
 
 
 
Chapter 6  Result and Discussion 
Dept. of Pharmaceutical Analysis 77 J.K.K. Nattraja College of Pharmacy 
Table No. 16: Hemolysis effect 
Quality Control Sample HE_LQC HE_HQC 
Nominal Concentration ng/mL 1.231 205.127 
Acceptance Range 1.046 174.358 
1.416 235.896 
Back Calculated Concentration 
(ng/mL) 
1.140 194.477 
1.242 201.220 
1.239 193.498 
1.179 197.122 
1.203 193.097 
1.240 199.161 
Mean 1.2072 196.4292 
SD 0.04154 3.29852 
% CV 3.44 1.68 
% Accuracy 98.06 95.76 
N 6 6 
 
Reagent stability 
The stability of the reagents which were used during the method validation 
was evaluated. The reagents were kept on bench top at room temperature on 
16Oct2017.After 12 days, six sets of LQC and HQC samples were processed using 
old reagents (prepared on 16Oct2017) and simultaneously calibration curve 
standards and  another six sets of LQC and HQC samples were processed using 
freshly prepared reagents (prepared on 28Oct2017) and analyzed.  
Based on the results, it was concluded that the below mentioned reagents 
were stable up to 12 days at room temperature.  
Note:  Enzyme Solution and 1.00% L-Ascorbic acid were prepared on the 
day of usage. 
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Reagent used for processing: 
 5mM Ammonium Acetate Buffer 
 0.5 M Sodium Acetate Buffer 
 1.00% L-ascorbic Acid 
 β-Glucuronidase Enzyme Solution 
 1M Sodium Hydroxide Buffer 
 Mobile Phase (ACN: Buffer :: 75:25%v/v) 
Within Batch Precision LQC: 2.86% and HQC: 2.65% 
%  Change LQC: 0.15% and HQC: 2.91% 
 
Acceptance Criteria  
The % change should not be more than ± 15% while comparing the mean of 
back calculated concentration of stability samples against the nominal concentration. 
Table No. 17: Reagent stability for Ezetimibe (After 12 days) 
Quality Control ID Fresh LQC Fresh HQC 
Stability 
LQC 
Stability 
HQC 
Nominal Concentration 
ng/mL 
1.231 205.127 1.231 205.127 
Acceptance Range 1.046 174.358 1.046 174.358 
1.416 235.896 1.416 235.896 
Back Calculated 
Concentration (ng/mL) 
1.243 206.576 1.253 217.310 
1.242 203.607 1.181 208.444 
1.260 205.562 1.198 217.558 
1.194 205.672 1.267 205.187 
1.236 199.558 1.259 205.492 
1.308 202.963 1.239 212.620 
Mean 1.2472 203.9897 1.2328 211.1018 
SD 0.03704 2.56249 0.03520 5.58655 
% Accuracy 101.31 99.45 100.15 102.91 
% CV 2.97 1.26 2.86 2.65 
% Change 0.15 2.91 
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STABILITIES: 
1. Short Term Stock Solution/Dilution Stability at Room Temperature 
a. Short Term Stock Solution Stability for Ezetimibe and Ezetimibe D4 
(Internal Standard) 
Diluent- Methanol: Water (80:20) 
Analyte 
 The stock solutions of Ezetimibe was prepared and kept on the bench at 
room temperature. After 29 Hrs stock solution of Ezetimibe was compared against 
fresh stock solution. 
 The % difference for stock solution of Ezetimibe was 0.16 %and 1.05 % at 
LLOQ and ULOQ Level respectively. 
Internal standard 
 The stock solutions of Ezetimibe D4 was prepared and kept on the bench at 
room temperature. After 29 Hrs stock solution of Ezetimibe D4 was compared 
against fresh stock solution.  
 The % difference for stock solutions of EzetimibeD4 at working solution 
concentration level was 1.94 %. 
Acceptance Criteria  
 The % difference for stability solution should be within ±10 % of response 
compared with the response of freshly prepared solutions. 
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Table No. 18: Short Term Stock Solution Stability of Ezetimibe and 
EzetimibeD4 
Concentration 
(ng/mL) 
Analyte Internal Standard 
LLOQ ULOQ Stock Dilution at 
working concentration 
Fresh Stock 0.504 250.915 12.766 
Stability Stock 0.504 250.948 12.650 
Correction factor 1.000 1.000 1.009 
 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock 
Area Response 
5911 5871 2446718 2442159 111239 111659 
6121 6300 2402585 2398532 107223 107907 
6176 6124 2296983 2328864 103635 105048 
6097 5769 2311450 2261491 104433 102343 
5620 5631 2347626 2376376 107153 107727 
5549 5837 2343762 2492601 105709 111203 
Mean 5912.3 5922.0 2358187.3 2383337.2 106565.3 107647.8 
SD 270.05 245.60 56672.41 81843.45 2701.41 3569.38 
%CV 4.57 4.15 2.40 3.43 2.53 3.32 
% Difference 0.16 1.05 1.94 
 
b. Short Term Stock Solution Stability of Ezetimibe Phenoxy Glucuronide  
Diluent- Methanol: Water (80:20) 
Metabolite 
 The stock solutions of Ezetimibe Phenoxy Glucuronide was prepared and 
kept on the bench at room temperature. After 49 Hrs stock solution of Ezetimibe 
Phenoxy Glucuronide was compared against fresh stock solution. 
 For Ezetimibe Phenoxy Glucuronide at LLOQ QC and HQC levels 
(equivalent to Ezetimibe concentration),one sample per each solution was processed 
(Respective solutions were spiked in water and extracted as per extraction 
procedure)  and six replicate injections were given from each vial for fresh and 
stability solutions. 
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The % difference for stock solution of Ezetimibe at LLOQQC and HQC level were -
2.82 % and -3.83 % respectively. 
Acceptance Criteria 
The % difference for stability solution should be within  ±10 % of response 
compared with the response of freshly prepared solutions. 
Table No. 19: Short Term Stock Solution Stability of Ezetimibe Phenoxy Glucuronide 
Concentration 
(ng/mL) 
Metabolite 
LLOQQC HQC 
Fresh Stock 0.503 201.395 
Stability Stock 0.505 202.679 
Correction factor 0.996 0.994 
 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock 
Area Response 
4410 4559 1522035 1475600 
4626 4254 1505906 1469517 
4280 4449 1533091 1492721 
4396 4101 1537246 1493528 
4436 4354 1566038 1518223 
4636 4414 1589005 1506287 
Mean 4464.0 4355.2 1542220.2 1492646.0 
SD 140.01 160.41 30299.68 18256.83 
%CV 3.14 3.68 1.96 1.22 
% Difference -2.82 -3.83 
 
c. Short Term Stock Dilution Stability for Ezetimibe and Ezetimibe D4 
(Internal Standard) 
Diluent- Methanol: Water (80:20) 
Analyte 
 The working solution of Ezetimibe at ULOQ and LLOQ concentration was 
prepared and kept on the bench at room temperature. After 26 Hrs the working 
solution at ULOQ and LLOQ concentration was compared against freshly spiked 
working solution. 
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 The % difference for the working solution of Ezetimibe at LLOQ and ULOQ 
concentration was -0.33 % and 1.16% respectively. 
Internal Standard 
 The working solution of Ezetimibe D4 was prepared and kept on the bench 
at room temperature. After 26 Hrs the working solution was compared against fresh 
working solution.  The % difference for the working solution of internal standard 
was 2.54 %. Acceptance Criteria  
 The % difference for stability solution should be within ±10 % of response 
compared with the response of freshly prepared solutions. 
Table No. 20: Short Term Stock Dilution Stability of Ezetimibe and Ezetimibe D4  
Concentration 
(ng/mL) 
Analyte Internal Standard 
LLOQ ULOQ Stock Dilution at 
working concentration Fresh Stock 0.504 250.915 12.766 
Stability Stock 0.504 250.948 12.650 
Correction factor 1.000 1.000 1.009 
 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock 
Area Response 
5911 6081 2446718 2390907 111239 109168 
6121 6286 2402585 2326714 107223 107207 
6176 5610 2296983 2360634 103635 108704 
6097 5828 2311450 2298235 104433 103207 
5620 5909 2347626 2480492 107153 110470 
5549 5642 2343762 2457644 105709 110895 
Mean 5912.3 5892.7 2358187.3 2385771.0 106565. 108275.2 
SD 270.05 259.76 56672.41 72036.55 2701.41 2810.31 
%CV 4.57 4.41 2.40 3.02 2.53 2.60 
% Difference -0.33 1.16 2.54 
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d. Short Term Stock Dilution Stability of Ezetimibe Phenoxy Glucuronide 
Diluent- Methanol: Water (80:20) 
Metabolite 
 The working solution of Ezetimibe Phenoxy Glucuronide at LLOQQC and 
HQC concentration was prepared and kept on the bench at room temperature. After 
47 Hrs the working solution at LLOQQC and HQC concentration was compared 
against freshly spiked working solution.  
 For Ezetimibe Phenoxy Glucuronide at LLOQ QC and HQC levels 
(equivalent to Ezetimibe concentration),one sample per each solution was processed 
(Respective solutions were spiked in water and extracted as per extraction 
procedure)and six replicate injections were given from each vial for fresh and 
stability solutions. 
 The % difference for stock solution of Ezetimibe at LLOQQC and HQC 
level were -2.27 % and 1.22 % respectively.  
Acceptance Criteria  
 The % difference for stability solution should be within ±10 % of response 
compared with the response of freshly prepared solutions. 
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Table No. 21: Short Term Stock Dilution Stability of Ezetimibe Phenoxy 
Glucuronide 
Concentration 
(ng/mL) 
Metabolite 
LLOQQC HQC 
Fresh Stock 0.505 201.915 
Stability Stock 0.509 199.763 
Correction factor 0.992 1.011 
 Fresh Stock Stability Stock Fresh Stock Stability Stock 
Area Response 
4224 4312 1630875 1605139 
4208 4218 1618657 1616316 
4241 4294 1604685 1644808 
4378 4427 1625562 1630306 
4602 4117 1613879 1623985 
4377 4272 1639016 1625392 
Mean 4338.3 4273.3 1622112.3 1624324.3 
SD 149.75 102.99 12311.44 13332.86 
%CV 3.45 2.41 0.76 0.82 
% Difference -2.27 1.22 
 
2. Long Term Stock Solution / Dilution Stability At Refrigerator  
a. Long Term  Stock Solution Stability for Ezetimibe and Ezetimibe D4 
Diluent:  Methanol 
Analyte 
 The stock solutions of Ezetimibe was prepared and stored at refrigerator 
temperature (2-8ºC). After 18 days the stock solutions of Ezetimibe was compared 
against fresh stock solutions of Ezetimibe. 
 The % difference for stock solution of Ezetimibe at LLOQ and ULOQ level 
were -2.20 % and 0.94 % respectively.  
Chapter 6  Result and Discussion 
Dept. of Pharmaceutical Analysis 85 J.K.K. Nattraja College of Pharmacy 
Internal Standard 
 The stock solutions of Ezetimibe D4 was prepared and stored at refrigerator 
temperature (2-8ºC). After 18 days the stock solutions of Ezetimibe D4 was 
compared against fresh stock solutions of Ezetimibe D4. 
 The % difference for stock solution of Ezetimibe D4 was 1.43 % at working 
solution concentration level. 
Acceptance Criteria  
 The % difference for stability solution should be within ± 10 % of response 
compared with the response of freshly prepared solutions. 
Table No. 22: Long Term Stock Solution Stability for Ezetimibe and Ezetimibe D4 
Concentration 
(ng/mL) 
Analyte Internal Standard 
LLOQ ULOQ Stock Dilution at 
working 
concentration Fresh Stock 0.504 250.915 12.766 
Stability Stock 0.503 251.703 12.788 
Correction factor 1.002 0.997 0.998 
 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock 
Area Response 
5911 6282 2446718 2392350 111239 107037 
6121 5761 2402585 2320336 107223 104695 
6176 5811 2296983 2311075 103635 105312 
6097 5771 2311450 2474739 104433 112182 
5620 5658 2347626 2417566 107153 110351 
5549 5341 2343762 2410384 105709 110097 
Mean 5912.3 5770.7 2358187.3 2387741.7 106565.3 108279.0 
SD 270.05 303.48 56672.41 62310.90 2701.41 3033.89 
%CV 4.57 5.26 2.40 2.61 2.53 2.80 
% Difference -2.20 0.94 1.43 
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b. Long Term Stock Solution Stability of Ezetimibe Phenoxy Glucuronide 
Diluent- Methanol: Water (80:20)  
Metabolite 
 The stock solutions of Ezetimibe Phenoxy Glucuronide was prepared and 
stored at refrigerator temperature (2-8ºC). After 20 days the stock solutions of 
ezetimibe phenoxy glucuronide was compared against fresh stock solutions of 
ezetimibe phenoxy Glucuronide. 
 For ezetimibe phenoxy glucuronide at LLOQ QC and HQC levels 
(equivalent to Ezetimibe concentration), one sample per each solution was processed 
(Respective solutions were spiked in water and extracted as per extraction 
procedure) and six replicate injections were given from each vial for fresh and 
stability solutions. 
 The % difference for stock solution of Ezetimibe at LLOQQC and HQC 
level were 3.25% and -7.01% respectively.  
Acceptance Criteria  
 The % difference for stability solution should be within ±10 % of response 
compared with the response of freshly prepared solutions. 
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Table No. 23: Long Term Stock Solution Stability of Ezetimibe Phenoxy 
Glucuronide 
Concentration 
(ng/mL) 
Metabolite 
LLOQQC HQC 
Fresh Stock 0.503 201.395 
Stability Stock 0.504 201.485 
Correction factor 0.998 1.000 
 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock Stability Stock 
Area Response 
4410 4550 1522035 1380058 
4626 4637 1505906 1443269 
4280 4618 1533091 1431025 
4396 4401 1537246 1445073 
4436 4820 1566038 1475458 
4636 4683 1589005 1433201 
Mean 4464.0 4618.2 1542220.2 1434680.7 
SD 140.01 139.36 30299.68 31124.72 
%CV 3.14 3.02 1.96 2.17 
% Difference 3.25 -7.01 
 
b. Long term Stock Dilution stability for Ezetimibe and Ezetimibe D4 
Diluent- Methanol: Water (80:20) 
Analyte 
 The working solutions of Ezetimibe at ULOQ and LLOQ concentration was 
prepared and stored in refrigerator temperature (2-8ºC). After 18 days the working 
solution of Ezetimibe at ULOQ and LLOQ concentration was compared against 
freshly spiked working solution. 
 The % difference for stock solution of Ezetimibe at LLOQ and ULOQ level 
were -0.85 % and 2.37 % respectively.  
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Internal Standard 
 Working solution of Ezetimibe D4 at working solution concentration level 
was prepared and stored at refrigerator temperature (2-8ºC). After 18 days the 
working solution of Ezetimibe D4 was compared against fresh working solution. 
The % difference for the working solution of internal standard was 3.08 %.  
Table No. 24: Long term Stock Dilution stability for Ezetimibe and Ezetimibe D4 
Concentration 
(ng/mL) 
Analyte Internal Standard 
LLOQ ULOQ Stock Dilution at working 
concentration 
Fresh Stock 0.504 250.915 12.766 
Stability Stock 0.503 251.703 12.788 
Correction factor 1.002 0.997 0.998 
 
Fresh 
Stock 
Stability 
Stock 
Fresh 
Stock 
Stability 
Stock Fresh Stock 
Stability 
Stock 
Area Response 
5911 6284 2446718 2386247 111239 111115 
6121 5942 2402585 2376302 107223 107225 
6176 5784 2296983 2399365 103635 107228 
6097 5814 2311450 2489216 104433 112496 
5620 5809 2347626 2436465 107153 110360 
5549 5469 2343762 2441644 105709 111808 
Mean 5912.3 5850.3 2358187.3 2421539.8 106565.3 110038.7 
SD 270.05 264.32 56672.41 42404.65 2701.41 2291.17 
%CV 4.57 4.52 2.40 1.75 2.53 2.08 
% Difference -0.85 2.37 3.08 
 
c. Long Term Stock Dilution Stability of Ezetimibe Phenoxy Glucuronide   
Diluent- Methanol: Water (80:20) 
Metabolite 
 The working solution of ezetimibe phenoxy glucuronide at LLOQQC and 
HQC concentration was prepared and stored at refrigerator temperature (2-8ºC). 
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After 20 days the working solution at LLOQQC and HQC concentration was 
compared against freshly spiked working solution.  
 Ezetimibe phenoxy glucuronide at LLOQ QC and HQC levels, one sample 
per each solution are processed (Respective solutions are spiked in water and 
extracted as per extraction procedure.)  and six replicate injections were given from 
each vial for fresh and stability solutions. 
 The % difference for stock solution of Ezetimibe Phenoxy Glucuronide at 
LLOQQC and HQC level were -1.57 % and 3.77 % respectively. 
Acceptance Criteria  
 The % difference for stability solution should be within ±10 % of response 
compared with the response of freshly prepared solutions. 
Table No. 25 : Long term Stock Dilution stability for Ezetimibe Phenoxy 
Glucuronide 
Concentration 
(ng/mL) 
Metabolite 
LLOQQC HQC 
Fresh Stock 0.505 201.915 
Stability Stock 0.516 198.300 
Correction factor 0.979 1.018 
 Fresh Stock Stability Stock Fresh Stock Stability Stock 
Area Response 
4224 4146 1630875 1626546 
4208 4275 1618657 1630614 
4241 4336 1604685 1640935 
4378 4540 1625562 1665148 
4602 4383 1613879 1663618 
4377 4499 1639016 1692177 
Mean 4338.3 4363.2 1622112.3 1653173.0 
SD 149.75 145.46 12311.44 25065.85 
%CV 3.45 3.33 0.76 1.52 
% Difference -1.57 3.77 
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3. Auto Sampler Stability 
 The Auto sampler stability of analyte for low and high quality control 
samples were evaluated by analyzing them using a set of freshly spiked and 
prepared calibration curve standards. The stability samples were stored in the auto-
sampler (10°C temperature). 
 Based on the results, it was concluded that the analyte were stable at auto 
sampler temperature (10°C) for 124 Hrs 38 Min.  
Acceptance Criteria 
 The % change should not be more than ±15% while comparing the mean of 
back calculated concentration of stability samples against the nominal concentration. 
 
 
 
Table No. 26 : Auto Sampler Stability for Ezetimibe (124 Hrs 38 Min) 
Quality Control ID Fresh LQC Fresh HQC Stability LQC Stability HQC 
Nominal concentration 
(ng/mL) 1.205 200.810 1.231 205.127 
Acceptance Range  1.024 170.689 1.046 174.358 
1.386 230.932 1.416 235.896 
Back Calculated 
Concentration 
(ng/mL) 
1.199 201.630 1.317 201.103 
1.206 201.062 1.320 207.682 
1.200 200.833 1.240 208.436 
1.270 199.809 1.329 208.468 
1.212 208.691 1.314 209.713 
1.174 208.252 1.266 210.119 
Mean 1.2102 203.3795 1.2977 207.5868 
SD 0.03205 3.99044 0.03591 3.30088 
% CV 2.65 1.96 2.77 1.59 
% Change 5.42 1.20 
 
Within Batch LQC: 2.77 % and HQC: 1.59 % 
%  Change LQC: 5.42  % and HQC: 1.20  % 
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4. Wet Extract Bench Top Stability 
 The wet extract bench top stability of analyte for low and high quality 
control samples were evaluated by analyzing them using a set of freshly spiked and 
prepared calibration curve standards. The stability samples were kept on bench (at 
Room temperature). 
 Based on the results, it was concluded that the analyte is stable at bench top 
(Wet extract) for 09 Hrs 04 Min. 
Acceptance Criteria:  
 The % change should not be more than ±15% while comparing the mean of 
back calculated concentration of stability samples against the nominal concentration. 
Within Batch Precision LQC: 2.87 % and HQC: 3.21% 
%  Change LQC: 5.56 % and HQC: 7.15  % 
 
Table No.  27 : Wet extract Bench top stability for Ezetimibe (09 Hrs 04 Min)  
Quality Control ID Fresh LQC 
Fresh 
HQC 
Stability 
LQC 
Stability 
HQC 
Nominal Concentration 
(ng/mL) 1.205 200.810 1.231 205.127 
Acceptance Range 1.024 170.689 1.046 174.358 1.386 230.932 1.416 235.896 
Back Calculated 
Concentration (ng/mL) 
1.199 201.630 1.307 212.230 
1.206 201.062 1.270 228.274 
1.200 200.833 1.288 219.604 
1.270 199.809 1.251 210.692 
1.212 208.691 1.331 224.972 
1.174 208.252 1.350 222.994 
Mean 1.2102 203.3795 1.2995 219.7943 
SD 0.03205 3.99044 0.03729 7.05774 
% CV 2.65 1.96 2.87 3.21 
% Change 5.56 7.15 
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5. Freeze thaw stability 
 To evaluate freeze thaw stability, sufficient individual aliquots of low and 
high quality control samples were stored in the freezer maintained at -65 ± 10°C. 
After at least 24 hours of freezing, six different aliquots of low and high quality 
control samples (stability samples) were retrieved from the freezer and thawed 
unassisted on bench at room temperature. This stability samples were refrozen for at 
least 12 hours under the same conditions. The freeze-thaw cycle was repeated for 
four more times, thereby making the samples undergo five freeze thaw cycles. After 
completion of fifth freeze thaw cycle, stability samples were processed along with a 
set of freshly spiked and prepared calibration curve standards and quality control 
samples (six different aliquots of low and high quality control samples) and 
analyzed in a single run.  
Based on the results, it was concluded that Ezetimibe was stable after five freeze 
thaw cycle. 
Within Batch Precision LQC: 4.97 % and HQC: 1.42 % 
%  Change LQC: -1.12 % and HQC:-0.33 % 
 
Acceptance Criteria:  
 The % change should not be more than ± 15% while comparing the mean of 
back calculated concentration of stability samples against the nominal concentration. 
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Table No. 28 : Freeze Thaw Stability for Ezetimibe after 5th Cycle 
Quality Control ID Fresh LQC Fresh HQC Stability LQC Stability HQC 
Nominal Concentration 
(ng/mL) 1.205 200.810 1.231 205.127 
Acceptance Range  1.024 170.689 1.046 174.358 1.386 230.932 1.416 235.896 
Back Calculated 
Concentration (ng/mL) 
1.199 201.630 1.167 206.384 
1.206 201.062 1.193 200.039 
1.200 200.833 1.299 207.247 
1.270 199.809 1.239 207.031 
1.212 208.691 1.264 202.545 
1.174 208.252 1.141 203.456 
Mean 1.2102 203.3795 1.2172 204.4503 
SD 0.03205 3.99044 0.06045 2.90858 
% CV 2.65 1.96 4.97 1.42 
% Change -1.12 -0.33 
 
6. Bench Top Stability 
 Bench top stability experiment was designed and conducted to cover the 
laboratory handling conditions that are expected for study samples.  
 The bench top stability of Ezetimibe for low and high quality control 
samples were evaluated by analyzing them using a set of freshly spiked and 
prepared calibration curve standard. 
 The Stability samples were kept on bench at room temperature. 
 Based on the results, it was concluded that the analyte is stable in plasma at 
room temperature for 10 Hrs 55 Min. 
Within Batch Precision LQC: 1.91 % and HQC: 2.91 % 
%  Change LQC: -2.53% and HQC: 0.02 % 
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Acceptance Criteria:  
 The % change should not be more than ± 15% while comparing the mean of 
back calculated concentration of stability samples against the nominal concentration. 
Table No. 29 : Bench top stability for Ezetimibe (10Hrs 55 Min) 
Quality Control ID Fresh LQC Fresh HQC Stability LQC Stability HQC 
Nominal Concentration 
(ng/mL) 1.205 200.810 1.231 205.127 
Acceptance Range 1.024 170.689 1.046 174.358 1.386 230.932 1.416 235.896 
Back Calculated 
Concentration ng/mL 
1.199 201.630 1.242 201.324 
1.206 201.062 1.190 197.628 
1.200 200.833 1.190 206.700 
1.270 199.809 1.210 210.461 
1.212 208.691 1.182 201.734 
1.174 208.252 1.185 213.173 
Mean 1.2102 203.3795 1.1998 205.1700 
SD 0.03205 3.99044 0.02286 5.96428 
% CV 2.65 1.96 1.91 2.91 
% Change -2.53 0.02 
 
7. Dry Extract Stability: 
 Dry Extract Stability was designed and conducted to cover the laboratory 
handling conditions that are expected for study samples.  
 The Dry Extract Stability of Ezetimibe for low and high quality control 
samples were evaluated by analyzing them using a set of freshly spiked and 
prepared calibration curve standard.  
 The Stability samples were kept in refrigerator. 
 Based on the results, it was concluded that the analyte is stable in dry extract 
at refrigerator temperature (5±3ºC) for 52 Hrs. 
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Within Batch Precision LQC: 2.45 % and HQC: 2.46 % 
%  Change LQC: 4.26 % and HQC: 1.59 % 
 
Acceptance Criteria:  
 The % change should not be more than ± 15% while comparing the mean of 
back calculated concentration of stability samples against the nominal concentration. 
Table No.30: Dry Extract Stability for Ezetimibe (52 Hrs) 
Quality Control ID Fresh LQC Fresh HQC Stability LQC Stability HQC 
Nominal Concentration 
(ng/mL) 1.205 200.810 1.231 205.127 
Acceptance Range 1.024 170.689 1.046 174.358 1.386 230.932 1.416 235.896 
Back Calculated 
Concentration ng/mL 
1.199 201.630 1.302 209.841 
1.206 201.062 1.288 200.418 
1.200 200.833 1.277 204.227 
1.270 199.809 1.332 212.818 
1.212 208.691 1.245 213.597 
1.174 208.252 1.257 209.487 
Mean 1.2102 203.3795 1.2835 208.3980 
SD 0.03205 3.99044 0.03144 5.11687 
% CV 2.65 1.96 2.45 2.46 
% Change 4.26 1.59 
 
8. Evaporator Stability 
 Evaporator Stability was designed and conducted to cover the laboratory 
handling conditions that are expected for study samples.  
 The Evaporator Stability of Ezetimibe for low and high quality control 
samples were evaluated by analyzing them using a set of freshly spiked and 
prepared calibration curve standard.  
 The Stability samples were kept at 40ºC in Evaporator. 
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 Based on the results, it was concluded that the analyte is stable in evaporator 
at 40ºC for 02 Hrs 03 Min. 
Within Batch Precision LQC: 4.39  % and HQC: 4.23  % 
%  Change LQC: 2.33 % and HQC: -2.10  % 
 
Acceptance Criteria:  
 The % change should not be more than ± 15% while comparing the mean of 
back calculated concentration of stability samples against the nominal concentration. 
Table No. 31 : Evaporator Stability for Ezetimibe (02 Hrs 03 Min) 
Quality Control ID Fresh LQC  Fresh HQC   Stability LQC  Stability HQC  
Nominal 
Concentration (ng/mL) 1.205 200.810 1.231 205.127 
Acceptance Range  1.024 170.689 1.046 174.358 1.386 230.932 1.416 235.896 
  Back Calculated 
Concentration ng/mL 
1.199 201.630 1.305 201.012 
1.206 201.062 1.308 208.225 
1.200 200.833 1.258 206.884 
1.270 199.809 1.167 193.585 
1.212 208.691 1.223 207.471 
1.174 208.252 1.290 187.689 
Mean 1.2102 203.3795 1.2585 200.8110 
SD 0.03205 3.99044 0.05520 8.49290 
% CV 2.65 1.96 4.39 4.23 
% Change 2.23 -2.10 
 
9. Long term stability of drug in matrix 
 To determine long term stability of Ezetimibe in human plasma, the quality 
control samples were prepared and stored in deep freezers maintained at -65 ± 10°C. 
Analysis has been carried out after the 85 days of storage. In the below tables data 
for long term stability for the analyte is provided. 
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Table No. 32 : Long Term Stability 
Quality Control ID Fresh LQC Fresh HQC Stability LQC Stability HQC 
Nominal Concentration 
(ng/mL) 1.205 200.810 1.231 205.127 
Acceptance Range  1.024 170.689 1.046 174.358 1.386 230.932 1.416 235.896 
Back Calculated 
Concentration (ng/mL) 
1.199 201.630 1.167 206.384 
1.206 201.062 1.193 200.039 
1.200 200.833 1.299 207.247 
1.270 199.809 1.239 207.031 
1.212 208.691 1.264 202.545 
1.174 208.252 1.141 203.456 
Mean 1.2102 203.3795 1.2172 204.4503 
SD 0.03205 3.99044 0.06045 2.90858 
% CV 2.65 1.96 4.97 1.42 
% Change -1.12 -0.33 
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CHROMATOGRAM – 01 CHROMATOGRAM FOR BLANK 
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CHROMATOGRAM – 02 CHROMATOGRAM FOR BLANK+IS 
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CHROMATOGRAM - 03  CHROMATOGRAM FOR CS-1 
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CHROMATOGRAM – 04 CHROMATOGRAM FOR CS-9 
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CHROMATOGRAM – 05 CHROMATOGRAM FOR -LLOQQC 
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CHROMATOGRAM – 06  CHROMATOGRAM FOR LQC 
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CHROMATOGRAM – 07 CHROMATOGRAM FOR M1QC 
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CHROMATOGRAM – 08 CHROMATOGRAM FOR MQC 
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CHROMATOGRAM – 09 CHROMATOGRAM FOR HQC 
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SUMMARY AND CONCLUSION 
 A simple, specific, rapid and sensitive analytical method for the determination 
of Ezetimibe in human plasma has been developed. 
 Most of the analytical methods reported, for quantization of Ezetimibe 
individually or simultaneously from human plasma, require laborious extraction 
procedure like Solid Phase extraction, long run time and high quantification 
limit. 
 The presented method provided excellent specificity and linearity with a limit 
of quantification of 0.503ng/ml for Ezetimibe. Although it was possible to go 
down much further in the LLOQ determination of the drug, the results obtained 
post subject analysis show that the LLOQ values selected are sufficient enough 
to give data for calculation of the required pharmacokinetic data and establish 
bioequivalence.  
 The other major advantage of this method over all those referenced is the short 
run time of 1.96 min which allows the quantization of over 200 plasma samples 
per day. 
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GLOSSARY 
Accuracy: The degree of closeness of the determined value to the nominal or 
known true value under prescribed conditions. This is sometimes termed trueness. 
Analyte: A specific chemical moiety being measured, this can be intact drug, 
biomolecule or its derivative, metabolite, and/or degradation product in a biologic 
matrix. 
Analytical run (or batch): A complete set of analytical and study samples with 
appropriate     number of standards and QCs for their validation. Several runs (or 
batches) may be completed in one day, or one run (or batch) may take several days 
to complete. 
Blank: A sample of a biological matrix to which no analytes have been added that is 
used to assess the specificity of the bioanalytical method. 
Biological matrix: A discrete material of biological origin that can be sampled and 
processed in a reproducible manner. Examples are blood, serum, plasma, urine, 
feces, saliva, sputum, and various discrete tissues. 
Cross-validation: Comparison validation parameters of two bioanalytical methods. 
Calibration standard: A biological matrix to which a known amount of analyte has 
been added or spiked. Calibration standards are used to construct calibration curves 
from which the concentrations of analytes in QCs and in unknown study samples are 
determined. 
Full validation: Establishment of all validation parameters to apply to sample 
analysis for the bioanalytical method for each analyte. 
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Internal standard: Test compound(s) (e.g. structurally similar analog, stable 
labeled compound) added to both calibration standards and samples at known and 
constant concentration to facilitate quantification of the target analyte(s). 
Limit of detection (LOD): The lowest concentration of an analyte that the 
bioanalytical procedure can reliably differentiate from background noise. 
Lower limit of quantification (LLOQ): The lowest amount of an analyte in a 
sample that can be quantitatively determined with suitable precision and accuracy. 
Matrix effect: The direct or indirect alteration or interference in response due to the 
presence of unintended analytes (for analysis) or other interfering substances in the 
sample. 
Method: A comprehensive description of all procedures used in sample analysis. 
Precision: The closeness of agreement (degree of scatter) between a series of 
measurements obtained from multiple sampling of the same homogenous sample 
under the prescribed conditions. 
Partial validation: Modification of validated bioanalytical methods that do not 
necessarily call for full revalidation. 
Processed: The final extract (prior to instrumental analysis) of a sample that has 
been subjected to various manipulations (e.g., extraction, dilution, concentration). 
Quantification range: The range of concentration, including ULOQ and LLOQ that 
can be reliably and reproducibly quantified with accuracy and precision through the 
use of a concentration-response relationship. 
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Quality control sample (QC): A spiked sample used to monitor the performance of 
a Bioanalytical method and to assess the integrity and validity of the results of the 
unknown Samples analyzed in an individual batch. 
Recovery: The extraction efficiency of an analytical process, reported as a 
percentage of the known amount of an analyte carried through the sample extraction 
and processing steps of the method. 
Reproducibility: The precision between two laboratories. It also represents 
precision of the method under the same operating conditions over a short period of 
time. 
Sample: A generic term encompassing controls, blanks, unknowns, and processed 
samples, as described below: 
Selectivity: The ability of the bioanalytical method to measure and differentiate the 
analytes in the presence of components that may be expected to be present. These 
could include metabolites, impurities, dégradants, or matrix components. 
Stability: The chemical stability of an analyte in a given matrix under specific 
conditions for given time intervals. 
Standard curve: The relationship between the experimental response value and the 
analytical concentration (also called a calibration curve). 
System suitability: Determination of instrument performance (e.g., sensitivity and 
chromatographic retention) by analysis of a reference standard prior to running the 
analytical batch. 
Upper limit of quantification (ULOQ): The highest amount of an analyte in a 
sample that can be quantitatively determined with precision and accuracy.  
